A framework for the reconstruction and analysis of tissue specific genome-scale metabolic models by Correia, Sara Alexandra Gomes
Sara Alexandra Gomes Correia
A framework for the reconstruction and
analysis of tissue specific genome-scale
metabolic models
Universidade do Minho
Escola de Engenharia
dezembro de 2016
Sa
ra
 A
lex
an
dr
a 
Go
m
es
 C
or
re
ia
A 
fr
am
ew
or
k 
fo
r t
he
 re
co
ns
tr
uc
tio
n 
an
d 
an
al
ys
is
 o
f t
is
su
e 
sp
ec
ifi
c 
ge
no
m
e-
sc
al
e 
m
et
ab
ol
ic
 m
od
el
s
Esta investigação foi financiada pela Fundação para a Ciência e Tecnologia através da concessão de 
uma bolsa de doutoramento (SFRH/BD/80925/2011), co-financiada pelo POPH – QREN – Tipologia 
4.1 – Formação Avançada – e comparticipado pelo Fundo Social Europeu (FSE) e por fundos nacionais 
do Ministério da Ciência, Tecnologia e Ensino Superior (MCTES).
 
 
 
 
M
inh
o 
| 
20
16
U
Sara Alexandra Gomes Correia
A framework for the reconstruction and 
analysis of tissue specific genome-scale 
metabolic models
Universidade do Minho
Escola de Engenharia
dezembro de 2016
Tese de Doutoramento
Doutoramento em Informática
Trabalho efetuado sob a orientação do:
Doutor Miguel Francisco de Almeida Pereira da Rocha
e do
Doutor Bruno Filipe Marques Costa
DECLARAC¸A˜O DE INTEGRIDADE
Declaro ter atuado com integridade na elaborac¸a˜o da presente tese.
Confirmo que em todo o trabalho conducente a` sua elaborac¸a˜o na˜o recorri
a` pra´tica de pla´gio ou qualquer forma de falsificac¸a˜o de resultados.
Mais declaro que tomei conhecimento integral do Co´digo de Conduta E´tica
da Universidade do Minho.
Universidade do Minho, dezembro de 2016.
Nome Completo: Sara Alexandra Gomes Correia

Acknowledgements /
Agradecimentos
Finalmente, mais um cap´ıtulo que se concretiza na minha vida. Ao longo
deste percurso encontrei ajuda e apoio em va´rias pessoas, que de uma forma
ou outra contribuiram para a concretizac¸a˜o deste projecto, a`s quais agradec¸o
do fundo do corac¸a˜o. Este e´ um espac¸o dedicado inteiramente a vo´s.
Em primeiro lugar, agradec¸o aos meus orientadores, Doutor Miguel Rocha
e Doutor Bruno Costa, por todo o apoio, orientac¸a˜o e cooperac¸a˜o ao longo
deste trabalho. Ao Doutor Miguel Rocha, um obrigada muito especial pelo
desafio lanc¸ado ha´ cinco anos atra´s. Sem o qual na˜o me encontraria, hoje, a
trabalhar nesta a´rea ta˜o fascinante e onde me sinto realizada.
Ao Centro de Engenharia Biolo´gica e ao Centro de Cieˆncia e Tecnologias
da Computac¸a˜o da Universidade do Minho por terem aceitado serem, em
diferentes fases, a minha instituic¸a˜o de acolhimento. A` Fundac¸a˜o para a
Cieˆncia e Tecnologia pela atribuic¸a˜o da bolsa de doutoramento que tornou
este trabalho poss´ıvel (SFRH/BD/80925/2011).
A todos os colegas do BIOSYSTEMS, grupo de investigac¸a˜o no qual
estive inserida durante estes quatro anos. Sem os momentos de descontrac¸a˜o
passados convosco, teria sido muito mais dif´ıcil suportar esta jornada.
Aos colegas do grupo de investic¸a˜o “Systems Biomedicine - EBI-UK”, em
especial ao Emanuel, que me acolheram em Cambridge durante 3 meses e
tornaram a experieˆncia de viver fora do pa´ıs ta˜o especial.
v
A` Carla, a` Cristiana e ao Paulo Vilac¸a pela vossa presenc¸a, ajuda, pacieˆncia,
conselhos e repreenso˜es, que vieram sempre nos momentos certos. Recordo,
com especial carinho os “puxo˜es de orelhas” da Carlinha. Mesmo quando a
distaˆncia foi muita, nunca vos mantivestes realmente longe (excepto quando
a videoconfereˆncia acaba porque algue´m se esquece do carregador). Obrigada
por tudo.
Um obrigada muito especial a` So´nia e Daniel Machado pelas discusso˜es
interessantes e pela partilha de conhecimento, ale´m das gargalhadas e da boa
disposic¸a˜o.
A` Ana Ala˜o, pelas “a´guas gazificadas com sabores” no acolhedor Pa˜o de
Forma, pelas conversas que entraram pela madrugada dentro e por nunca me
deixares “Alone”. Ao Rafael Pereira, o meu paciente vizinho da frente na
sala de trabalho, obrigada pela boa disposic¸a˜o e simpatia. Aos companheiros
do cafe´, com boas conversas a acompanhar, Daniel Gomes e Joa˜o Marcos,
obrigada tambe´m a vo´s.
Agradec¸o aos meus amigos, em especial a` Taˆnia e a` Marisa pelo apoio e
motivac¸a˜o. A` minha “irma˜” Sandrina, que sempre acreditou em mim, mesmo
na˜o sabendo do que eu andei por aqui a fazer.
Um obrigada muito especial a toda a minha famı´lia, que sempre me apoiou
em todos os momemtos.
Finalmente, serei eternamente grata aos treˆs homens da minha vida.
O meu pai, que desde sempre acreditou em mim. O meu melhor amigo,
companheiro e marido, Filipe, por ser o meu pilar. E por u´ltimo, o Gabriel,
meu filho, por ser o meu azimute.
vi
Abstract
In recent years, the development of novel techniques for genome sequenc-
ing and other high-throughput methods has enabled the identification and
quantification of individual cell components. Genome-scale metabolic mod-
els (GSMMs) have been developed for several organisms, including humans.
Under the framework of constraint-based modeling, these have provided
phenotype prediction methods, useful in fields as metabolic engineering and
biomedical research, spanning tasks as drug discovery, biomarker identifica-
tion and host-pathogen interactions, and targeting diseases such as cancer,
Alzheimer, or diabetes.
However, these methods have been limited, since the human body has a
diversity of cell types and tissues making the development of specific models
an imperative. Methods to provide phenotype simulation with the integration
of omics data and to automatically generate tissue-specific models, based on
generic human metabolic models and a plethora of omics data, have been
proposed. However, their results have not been adequately and critically
evaluated and compared. Moreover, their usage is restricted to users with
computer science skills, since they are not available in user-friendly software
platforms.
In this work, an open-source software framework for the integration of
GSMMs with omics data has been provided. It contains methods for the
processing and integration of data with models, for the reconstruction of
tissue-specific GSMMs and for phenotype simulation using omics data. A
user-friendly graphical interface is provided for non-programming users to be
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able to run these methods, while an open programming interface allows the
community to contribute.
The methods have also been validated and compared in representative case
studies, being studied the effects of data sources and algorithms in the final
results. In particular, glioblastoma has been selected as a more comprehensive
case study, where specific models were generated for a representative cell line
using different approaches. These have been compared and integrated into
a consensus model, which has been further used for analysis and to support
phenotype simulation. The results allow insights into cancer metabolism and
possible routes towards drug discovery.
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Resumo
Nos u´ltimos anos, o desenvolvimento de novas te´cnicas de sequenciac¸a˜o
geno´mica e outros me´todos experimentais de alto de´bito teˆm permitido a
identificac¸a˜o e quantificac¸a˜o de componentes celulares. Um conjunto de
Modelos Metabolicos a` Escala Genomica (MMEG) teˆm sido desenvolvidos
para mu´ltiplos organismos, incluindo os seres humanos. Recorrendo a` mo-
delac¸a˜o com base em restric¸o˜es, estes teˆm fornecido me´todos de predic¸a˜o do
feno´tipo, que teˆm sido u´teis na a´rea da engenharia metabolica e investigac¸a˜o
biome´dica, abordando tarefas como a descoberta de farmacos, a identificac¸a˜o
de biomarcadores e a interac¸a˜o entre agentes patoge´nicos e hospedeiros, e
doenc¸as como o cancro, Alzheimer ou diabetes.
Contudo, estes me´todos teˆm a sua aplicac¸a˜o limitada, dado que o corpo
humano e´ constitu´ıdo por diversos tecidos e tipos de ce´lulas, tornando essencial
o desenvolvimento de modelos especificos. Neste contexto, teˆm surgido
me´todos que permitem a simulac¸a˜o do feno´tipo com integrac¸a˜o de dados
omicos, assim como a reconstruc¸a˜o de modelos espec´ıficos baseados num
modelo gene´rico e em conjuntos de dados omicos. Todavia, os seus resultados
na˜o foram ainda comparados e avaliados sistematicamente. Ale´m disso, a sua
utilizac¸a˜o esta´ restrita a utilizadores com competeˆncias computacionais, uma
vez que na˜o existe nenhuma plataforma de software de fa´cil utilizac¸a˜o.
Neste trabalho, foi desenvolvida uma plataforma de software de acesso
livre, que permite a integrac¸a˜o de MMEGs com dados omicos. Esta plataforma
conte´m me´todos para o precessamento e integrac¸a˜o dos dados com os modelos,
reconstruc¸a˜o de MMEG para tecidos espec´ıficos e simulac¸a˜o do fe´notipo
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utilizando dados omicos. Foi desenvolvida uma interface gra´fica que permite
a utilizac¸a˜o destes me´todos por na˜o programadores. A comunidade pode
ainda contribuir para a sua extensa˜o atrave´s da interface disponibilizada.
Os me´todos foram validados e comparados com outros estudos, sendo
analisados os efeitos que as fontes de dados e os algoritmos teˆm nos resultados
finais. Em particular, foi selecionado como caso de estudo mais abrangente
a reconstruc¸a˜o do modelos metabolicos, usando diferentes abordagens, para
uma linha celular do glioblastoma. Posteriormente, estes modelos foram
comparados e integrados num modelo consenso, que foi utilizado para ana´lise
e simulac¸a˜o de feno´tipos. Os resultados obtidos permitem aprofundar o
conhecimento do metabolismo do cancro e apontam poss´ıveis caminhos para
a descoberta de novos fa´rmacos.
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Chapter 1
Introduction
In this brief introduction, the contextualization of this work
and the main objectives to pursue during this thesis are
presented. Also, a general overview of the next chapters is
provided.
1.1 Context and motivation
The mathematical modelling of cells has been traditionally achieved through
the use of dynamic models. However, since these require kinetic information
typically not available, their applicability is limited to small-scale systems
[1]. As an alternative, recent efforts allowed the development of genome-scale
metabolic models for several organisms (including humans). These have
been used to predict cellular metabolism under some simplifying assumptions,
namely considering the cell to be in steady-state, i.e. the concentrations of
all intracellular compounds are assumed to remain constant throughout time.
Together with the known stoichiometry and reversibility of the reactions, this
is used, in a constraint-based framework, to determine the possible values
for the reaction fluxes. Therefore, cellular behaviour can be predicted using
methods such as Flux Balance Analysis (FBA) [2]. Stoichiometric models
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and simulation methods have been thoroughly used in Metabolic Engineering
[3], but also in other applications related to biological discovery and data
analysis [4, 5, 6].
Recently, this effort has been extended with the development of four inde-
pendent human metabolic models [7, 8, 9, 10]. These models aim to represent
the metabolism of the most complex multicellular organisms, including a set
of biochemical reactions that may occur in distinct tissues or cell types. Over
the last years, they have already shown to be useful in biomedical applications,
such as in selecting drug targets for hypercholesterolemia [7], in predicting
metabolic markers for inborn errors of metabolism [11], and in the study of
the Warburg effect in cancer cells [12].
Despite the recent advances in the understanding of human metabolism
provided by these models, it is undeniable that the usefulness of these models
depends on the capability to address the phenotype simulation of different
cell types. This challenge was firstly addressed in [13], where the generic
model from [7] is integrated with gene expression and proteomics data to
predict the metabolic behaviour of human tissues, such as the liver or the
kidney. In the following years, several approaches [14, 15] have been proposed
for phenotype simulation with the integration of omics data to improve the
prediction quality. However, these methods only allow to characterize the
normal physiological behaviour of a cell type and can not be used to simulate
the effects of genetic or environmental perturbations, a feature essential for
biomedical research.
Therefore, there is a need for reconstructing tissue-specific metabolic
models that can be used to simulate the phenotype of distinct cell types in
several conditions. In 2010, a model-building algorithm [16] was proposed to
tackle this task, taking as its basis a generic model and heuristically pruning
it to derive a sub-model that is as consistent as possible with available
experimental data. This algorithm was used to construct a model for liver
cell, as a validation case study. A different approach, relying more on manual
curation, has been followed by Gille and co-workers [17] with the same final
result, a liver cell model, but showing more accurate predictions.
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The previous approach has been applied to the reconstruction of the
models of distinct types of human neurons [18], creating models of brain
energy metabolism relevant to the study of Alzheimer’s disease, and also in
studying the metabolic changes and the host-pathogen interactions occurring
during tuberculosis [19].
In spite of these results, the heuristic nature and limited accuracy of the
method from [16], together with the results from [17], show that there is the
need for more consistent methods for the (semi)-automatic reconstruction of
tissue-specific metabolic models, a task that will be targeted in this work.
Additional approaches have been proposed in the following years [9, 20,
21, 22, 23]. However, the comparison of the results is not trivial since each
approach uses specific data types as source data. Furthermore, each method
is evaluated with specific case studies and data sets in their own publications.
In this work, we propose the development of an integrated framework
for the reconstruction of tissue-specific metabolic models and phenotype
simulation integrating omics data. Moreover, a graphical interface will be
provided for the non-programmers users to be able to run these methods. In
the end, we will use this framework to reconstruct a genome-scale metabolic
model for one of the most aggressive brain cancers - the glioblastoma.
1.2 Research aims
In this context, the aim of this work will be to develop and systematically
evaluate methods and computational tools that allow the reconstruction
of genome-scale metabolic models for specific cell types/ tissues and their
application in biomedical research. Moreover, phenotype simulation with
omics integration methods will also be implemented. We will develop an
integrated computational platform that can be used by researchers to build
and validate models using distinct data and use those in different case studies.
As a case study, a glioblastoma metabolic model will be reconstructed using
the methods presented in the developed framework.
4 Introduction
This work will, therefore, encompass the following scientific/ technological
objectives:
• To devise a computational framework, including tools to load and
transform omics data, as well as to integrate them with metabolic
models. The data can be specific knowledge on metabolic systems
collected from literature (manually) or experimental data from relevant
phenotypes – gene expression, proteomics, metabolomics, fluxomics.
Several file formats must be supported, such as the Human Protein
Atlas files, XML files from the Human Metabolome Database and generic
text files (using comma/tab separators).
• To develop computational tools that will allow the reconstruction of
genome-scale metabolic models for specific cell types/ tissues and the
phenotype prediction using omics data to improve the results. These
algorithms will be supported by the infrastructure from the previous
step.
• To implement the methods from the previous steps within the context
of OptFlux [24], a metabolic engineering reference platform developed
within the group.
• To systematically evaluate and compare the previous methods using
different omics data as input, with the purpose of finding the best
combination of method and omics data to be used in other case studies.
• To reconstruct genome-scale metabolic models for cells with the glioblas-
toma phenotype, providing their comparison and analysis aiming to
uncover insights regarding their metabolism and possible drug discovery
efforts.
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1.3 Thesis outline
This manuscript has been structured in seven chapters addressing all of the
previously stated aims.
The thesis begins in the current chapter (Chapter 1) with a general
introduction, together with the statement of the proposed aims and an outline
of the manuscript’s structure.
Chapter 2 presents a thorough report of the state of the art of the set of
subjects involved in this project, namely: metabolic model reconstruction,
constraint based modelling of metabolic systems, phenotype simulation meth-
ods, context-specific model reconstruction approaches and applications of
such methods.
In Chapter 3, the software tools developed during this thesis are ex-
plained in detail. These tools are made available in a powerful, yet accessible
framework, for the community to use and extend.
Chapter 4 presents the evaluation of the phenotype simulation methods
using omics data to improve the predictions.
Chapter 5 presents a critical evaluation of methods for the reconstruction
of tissue-specific metabolic models and the consistency between several omics
data sources.
The reconstruction of the glioblastoma metabolic models is presented in
chapter 6. Here, we detail the reconstruction process, validate and compare
the models with other published ones, and use it to gain insight on cancer
cell metabolism.
Finally, Chapter 7 presents the general conclusions derived from this work
and perspectives for future work.

Chapter 2
State of the Art
This chapter presents the concepts related with systems
biology, constraint-based modeling and omics data. The
reconstruction process of genome-scale metabolic models
is explained. Besides, a summary of the most important
methods for the tissue-specific reconstruction models and
phenotype simulation integrating omics data are presented.
2.1 Systems biology
Nature is composed of several different species that crossed biological evolution
along the years. Each individual is composed of elemental building blocks
of life - the cells [25]. In the last decades, deep knowledge about individual
cellular components and their functions provided by biological research have
clearly shown that most biological processes occur in complex interactions
between cellular constituents, such as proteins, deoxyribonucleic acid (DNA)
and ribonucleic acid (RNA) molecules [26].
In this context, Systems Biology (SB) arises as an interdisciplinary field
of study that tries to explain the complex interactions within biological sys-
tems [27]. The evolution of SB has been supported by the development of
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novel techniques for genome sequencing and other high-throughput meth-
ods, that have generated the so called ”omics” data, such as genomics [28],
transcriptomics [29], proteomics [30], metabolomics [31], and fluxomics [32].
The combination of these data and the knowledge of cellular functions
allowed the construction of biological networks or of models capable to simulate
the cell behaviour [33].
Biological networks/models can be broadly categorized into three types
[34] :
1. metabolic: contains all the biochemical reactions that occur in the cell.
These networks describe the consumption/synthesis of metabolites that
are essential for the growth and cell survival;
2. regulatory : aims to represent the regulatory interactions between regu-
latory elements (e.g. transcription factors, promoters) and their target
genes, for instance A→ B means that gene A controls the expression
of gene B;
3. signalling : represents the reactions or ”signalling events” (such as
phosphorylation or ubiquitinations) in a network that regulate how a
cell responds to its environment, through cascades of information flow.
None of these networks are independent and the combination of the differ-
ent levels allows for a deeper understanding of cellular processes. However,
the integration of all these information into models increases their complexity,
while the current modeling capabilities of all these networks prevent their
inference in a genome level [6].
Therefore, in the following the focus will rely on metabolic models that
are the most developed and the ones addressed in this work.
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Genome-Scale Metabolic Models (GSMMs) are composed by metabolites and
reactions that allow the representation of all biochemical processes of the cell.
The development of GSMMs starts with genome sequencing [35, 36]. Based
on the genome sequence, a functional annotation is performed through the
information present in databases such as GenBank [37], Entrez Gene [38]
and BioCyc [39]. Next, the set of reactions and the gene-protein-reaction
(GPR) associations are collected using information presented in databases
such as KEGG [40], BRENDA [41], UniProt [42, 43], MetaCyc [44] and also
literature.
GPR associations are composed by logical rules, which represent the
relationship between genes, proteins and reactions. This allows to include
information about the transcriptional/ translational level, through the refer-
ence to the enzymes that catalyse the reactions and the genes encoding those
enzymes, into the metabolic models.
Normally, in GSMMs, a GPR association contains only the relationship
between genes and a reaction using the logical operators AND or OR to
represent the dependency of genes of each reaction. For instance, if reaction
r1 has the GPR g1OR(g2ANDg3), this means that the reaction r1 occurs only
when gene g1 or both genes g2 and g3 are expressed. The inclusion of GPRs
within GSMMs is essential to allow the phenotype prediction of the cell under
different genetic conditions, such as gene knockouts and over/underexpression.
Once the draft metabolic model is generated, a set of simulations are
required to validate the model. Based on the results, the model may be
improved or optimized by the addition/ removal of reactions (Figure 2.1).
Over the last decade, the advances in DNA sequencing techniques and the
sequencing costs have decreased allowing to increase the number of organisms
having their genome sequenced [45, 46] and, therefore, the number of GSMMs
being reconstructed [47].
Nowadays, several tools such as Model SEED [48] or Merlin [49] are avail-
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Figure 2.1: Model reconstruction cycle.
able to support a faster genome-scale metabolic models reconstruction. The
Metabolic Models Reconstruction Using Genome-Scale Information (Merlin)
[49], developed in our group, is a freeware tool that supports the reconstruc-
tion process, including the functional genomic annotation of the genome and
subsequent construction of the portfolio of reactions.
Metabolic models have been used to simulate the cell phenotype under
different environmental conditions and genetic changes [50]. These models, to-
gether with strain optimization tools, allow the identification of genetic targets
for increasing yields productivities and robustness in industrial biotechnology
processes [51, 52].
Additionally, over the last years, metabolic models have been used to
understand some phenotypes associated with diseases [22], to find drug targets
[20] and to study the relationship between different organisms [53] and cell
types [18].
2.2.1 Human metabolic models
The human species is one of the most complex organisms since the number
of genes, types and diversity of cells are huge. After the human genome
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sequencing and its annotation [54, 55], efforts have been made in the last
decade to reconstruct human genome-scale metabolic models. Until now, four
human GSMMs has been proposed [7, 8, 9, 10] and have been used to study
human physiology and pathology.
The reconstruction of the first human GSMM was published in 2007 [7],
under the name of Recon 1. This metabolic model accounts for the functions
of 1.905 genes, 2.766 metabolites, and 3.742 metabolic and transport reactions
and was reconstructed based on an extensive collection and evaluation of
genomic and bibliomic data.
The model was validated through the simulation of 288 known metabolic
functions present in different cells and tissue types. All related information is
available in the BIGG database [56] (http://bigg.ucsd.edu/).
A few months later, a new metabolic model was published by Ma et al.
[57], called the Edinburgh Human Metabolic Model (EHMM). This network
was manually reconstructed by integrating genome annotation from different
databases and metabolic reactions information from literature. In the first
step of the reconstruction, the authors mainly collected all information from
the databases KEGG [58], UniProt [43] and HGNC (HUGO Gene Nomen-
clature Committee) [59]. The second step of the reconstruction integrated
information from the Enzymes and Metabolic Pathways database [60]. In 2010,
the compartmentalization of the EHMM was completed [8]. The compartmen-
talization required the association of metabolic reactions to different cellular
organelles and transport reactions that were added to allow the exchange of
metabolites between such organelles.
In 2012, a new metabolic model of human cells, the iHuman1512 [9],
was developed based on the Human Metabolic Reaction (HMR) database.
This database has been constructed from the two previous models, also
incorporating information from KEGG and HumanCyc [61]. During the
construction of this database, metabolites with lacking identifiers to external
databases were left out along with their corresponding reactions.
This database has been expanded through the incorporation of the lipid
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metabolism, which accounts for 59 fatty acids rather than relying on generic
fatty acid metabolites. The inclusion of fatty acids allowed the integration
with lipidomics data and helped in understanding the contribution of lipids
to the development of diseases [62]. The resulting HMR database version 2.0
contains 3,765 genes, 6,007 metabolites (3,160 unique metabolites) and 8,181
reactions, with 74% of the reactions associated to one or more genes.
In 2013, a new model has been proposed by Thiele et al. [10]- Recon
2. The Recon 2 is a community-driven expansion of the previous human
metabolic model Recon 1, with several additions from other sources, such
as the previous model EHMN [8], Hepatonet1 [17], a manually curated and
functional model of hepatocyte metabolism, the acylcarnitine–fatty acid
oxidation module [63], and the small intestinal enterocyte reconstruction [64].
Recon 2 accounts for 1,789 enzyme-encoding genes, 7,440 reactions and 2,626
unique metabolites distributed over eight cellular compartments. Recently,
a new Recon 2 model version was published during 2015 with significant
changes on GPR associations (https://vmh.uni.lu).
Based on the information available, a summary of the different human
metabolic models is presented in following table (Table 2.1).
Table 2.1: Number of reactions, metabolites, genes and compartments present
in the available human metabolic models. Species representing the same
metabolite in different compartments are here considered as different metabo-
lites.
Recon 1 EHMM HMR 2.0 Recon 2.04
Reactions 3, 742 6, 216 8, 181 7, 440
Metabolites 2, 766 6, 522 6, 007 5, 063
Genes 1, 905 2, 693 3, 765 2, 140
Compartments 8 9 8 8
Besides these models, human metabolic information is also available in
Reactome [65, 66] and HumanCyc [61] databases. However, this information
is not organized as a model and, therefore, can not be used to support
phenotypes simulations.
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Human GSMMs have been widely used in studies involving the discovery
of biomarkers [11], generating context-specific metabolic models [14] and
elucidating one of the most important and puzzling hallmarks of cancer, the
Warburg effect [12].
2.3 Constraint-based modeling
Biological networks/models can be analysed using different modeling for-
malisms depending on the question to be answered, the biochemical knowledge
and the availability of experimental data [67]. Mathematically, a metabolic
model can be represented as a matrix (Sm×n) ofm metabolites and n reactions,
Sm×n =

s1,1 s1,2 · · · s1,n
s2,1 s2,2 · · · s2,n
...
...
. . .
...
sm,1 sm,2 · · · sm,n

where each element si,j is the stoichiometric coefficient of the i
th metabolite
on the jth reaction.
A detailed quantitative description of the biological processes can be
reached by ordinary differential equations [68]. However, kinetic parameters
are rarely available for large-scale networks.
The analysis of the metabolic models can be simplified considering the
steady-state assumption, i.e., the metabolites concentration remains constant
over time [69]. Considering this assumption, it is possible to obtain flux
distributions for the vector v, solving the system equations
S.v = 0 (2.1)
where S is the matrix of stoichiometric coefficients, for a set of m metabolites
and a set of n reactions, and v is the vector of n reaction rates (fluxes).
Additionally, the maximum and the minimum flux values can be imposed
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for each reaction to define the thermodynamic feasibility (directionality) and
flux capacity [70], as follows:
0 ≤ vi ≤ vmaxi , ∀i ∈ Nirreversible (2.2)
vmini ≤ vi ≤ vmaxi , ∀i ∈ Nreversible (2.3)
where vi is the flux carried over reaction i, Nirreversible and Nreversible are the
sets composed of all reversible and irreversible reactions, respectively, and
vmini and vmaxi are the lower and upper bounds for the flux over reaction i.
Some flux distributions are impossible to occur in vivo. Therefore, ad-
ditional constraints should be added to represent the cells environmental
conditions, for instance, the nutrient uptake rates. Constraint-Based Mod-
elling (CBM) [71] determines possible flux distributions which are optimal to
a specific criteria that satisfies the previously defined constraints (Figure 2.2).
For instance, to find the flux distributions that correspond to the maximum
growth rate of an organism.
Figure 2.2: Constraint-based modeling.
One of the most widely used CBM approaches is Flux Balance Analysis
(FBA) [2, 72], which can be represented as:
max/min Z
s.t. : S.v = 0
vi,min < vi < vi,max
(2.4)
where Z = cTv is the objective function (a linear combination of fluxes, where
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c is a vector of weights indicating how much each reaction contributes to the
objective function). Usually the Z = vbiomass when the objective function is
the maximization of growth rate.
The assumption of maximal growth is acceptable under wild-type condi-
tions. However, sometimes the organism is subjected to genetic perturbations,
such as gene deletions. To deal with mutant strains, Segre` and coworkers
introduced the Minimization Of Metabolic Adjustment (MOMA) method [73].
This method minimizes the sum of the squared differences between the wild
type (typically calculated with FBA or given as a reference flux distribution)
and the mutant flux distributions, thus defining a quadratic objective function,
which translates into a quadratic programming (QP) problem.
With a similar approach, the Regulatory On/Off Minimization (ROOM)
[74] algorithm tries to minimize the number of significantly changed fluxes,
relative to the original flux distribution. This approach requires the intro-
duction of binary variables in the objective function, thus converting the LP
problem into a MILP one.
Both methods try to minimize the flux distribution difference between the
wild type and the mutant cell based on the assumption that the organism
will try to adjust its behaviour with the minimum possible effort.
2.4 Omics information
The abundance of biological information generated by high-throughput studies
has enabled the identification and quantification of the individual components
(genes, proteins and metabolites) of biological systems. These data are globally
known as ’omics’ data, and include genomics, transcriptomics, proteomics and
metabolomics, just to name the most popular. The challenge of using omics
data lies on the difficulty to integrate all these data. Nevertheless, when this
is possible, such data allows a better understanding of the cell as a whole.
An overview of some techniques and main sources of information in each
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’omic’ field, is summarized in Table 2.2.
Table 2.2: Techniques and main sources of information for each omic platform.
Field Techniques Databases
Genomics Microarray GEO
RNA-sequencing ArrayExpress
GeneNote
TCGA
Proteomics Mass Spectrometry HPA
Gel-based protein separation HPRD
Metabolomics Gas Chromatography–Mass Spec-
trometry
HMDB
Nuclear Magnetic Resonance
Overall, different types of omics data allow a better understanding of
many complex biological processes occurring in the cells and can be used in
the reconstruction process of metabolic models.
2.4.1 Transcriptomics
Transcriptomics are, certainly, the most widely available type of omics data.
Using DNA microarrays or other techniques, such as RNA-sequencing, allows
the quantification of the expression levels of genes inside cells in different
conditions [75, 76].
One of the most well-know databases for gene expression data is the Gene
Expression Omnibus (GEO) [77]. This is a public repository that archives
and distributes microarray, next-generation sequencing and other forms of
high-throughput functional genomic data. In addition, a set of computer
web-applications are available to query and download the gene expression
patterns stored in GEO (http://www.ncbi.nlm.nih.gov/geo/).
The ArrayExpress Archive [78] is another repository which contains func-
tional genomics experiments, including gene expression, where it is possible
to query and download data in standard formats.
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Using tools such as R/Bioconductor [79, 80] (e.g. the limma package) on
data from the previously mentioned databases, it is possible to understand
which genes are differentially expressed between different cell types or pheno-
types, for instance normal vs cancer cells. However, this relative expression
is unable to provide answers to the questions: “ Which are the genes that
are expressed in different phenotypes and what are their absolute levels of
expression?”.
The Gene Expression Barcode (GEB) [81] provides absolute measurements
for most annotated genes, organized by tissue types, including diseased tis-
sues. Considering standardized values obtained from GEO and ArrayExpress
repositories, it is possible to convert these expression values to silenced and
expressed genes applying a threshold. Moreover, it is possible to convert data
from a single microarray into expressed/unexpressed values for each gene.
2.4.2 Proteomics
mRNA molecules are not always translated into proteins [82], and therefore
amount of protein produced depends on the gene expression and the current
state of the cell. Thus, the knowledge about the amounts of proteins in the
cell, provided by proteomics data [83], is of foremost relevance. These data
can confirm the presence of proteins and quantify the amount of proteins
within a cell.
The Human Protein Atlas (HPA) [84] is a database with millions of
high-resolution images showing the spatial distribution of protein expression
profiles in normal tissues, cancer and cell lines for human cells.
Also, the Human Protein Reference Database (HPRD) [85] database
represents and integrates information for each protein in the human proteome.
All published data available in this database has been manually extracted from
the literature, interpreted and analyzed. Nowadays, this database accounts
for more than 30.000 protein entries.
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2.4.3 Metabolomics
Another source of information is provided by metabolomics data which allows
the identification and quantification of the small molecules present in the
cells, tissues, organs and biological fluids using techniques such as Nuclear
Magnetic Resonance (NMR) spectroscopy and Gas Chromatography-Mass
Spectrometry (GC-MS) [86]. Those metabolites contribute for the design of
metabolic pathways and the understanding of the interaction of proteins with
environmental cell factors (e.g. drug exposure).
The Human Metabolome Database (HMDB) [87] contains spectroscopic,
quantitative, analytic and molecular-scale information about human metabo-
lites, their associated enzymes or transporters, their abundance and disease-
related properties.
2.4.4 Others sources
There are other repositories of information, specialized in specific diseases such
as cancer (“The Cancer Genome Atlas”) and diabetes (“Diabetes Genome
Anatomy Project”). The Cancer Genome Atlas (TCGA) [88] is a collaborative
effort between many organizations to map the genomic changes that occur
in major types and subtypes of cancer. Besides, the data that have been
generated by TCGA’s network are available in the TCGA Data Portal [89],
that provides a platform for searching, downloading, and analyzing data
that contains clinical information, genomic characterization data and high-
throughput sequencing analysis of the tumor genomes.
2.5 Simulation methods
Several diseases such as cancer, diabetes, hypertension and heart diseases
can be related with the abnormal metabolism of cells [90, 12]. Furthermore,
human metabolism is complex and involves a large number of reactions that
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are highly interconnected by common metabolites [91]. Since the function of
each tissue is so different, it is also expected that the metabolism of each cell
type will also be distinct. However, the lack of information on tissue-specific
metabolite exchanges is still a limitation to employ CBM methods [13].
Over the last decade, some approaches have been developed to integrate
omics data to improve the phenotype prediction. In this section, the most
relevant simulation methods it will be presented that give the flux distribution
that better represent the data used as input.
2.5.1 iMAT
The reconstruction of tissue-specific metabolic models and the usage of omics
data to improve the phenotype predictions is not new. Indeed, in 2008, Shlomi
et al [13] developed the first approach called Integrative Metabolic Analysis
Tool (iMAT), to predict the metabolic activity in ten human tissues: brain,
heart, kidney, liver, lung, pancreas, prostate, spleen, skeletal muscle and
thymus.
This approach integrates information of gene and protein expression
with the existing human metabolic network model - Recon 1. The gene
expression information was retrieved from the GeneNote (Gene Normal Tissue
Expression) [92] database, while the Human Protein Reference Database
(HPRD) was used as a source for proteomics data [13].
The post-transcriptional regulation is not reflected in the gene and protein
expression data, so this method treats the expression levels of enzymes as cues
for the probability that their associated reactions have metabolic flux. The
highly, lowly and moderately expressed genes values are converted to 1, -1
and 0, respectively, through the gene-protein rules, replacing the logical ’and’
and ’or’ operators with ’max’ and ’min’ expressions. This transformation
resulted in two subsets of reactions in the model: RH (highly expressed) and
RL (lowly expressed).
The reconstruction of a context-specific metabolic network is done by
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solving an optimization problem, using a Mixed Integer Linear Programming
(MILP) formulation, to find a steady-state metabolic flux distribution that
satisfies the stoichiometric and thermodynamic constraints embedded in the
model, the number of flux-carrying reactions associated with highly expressed
enzymes is maximized and the number of flux-carrying reactions associated
with lowly expressed genes is minimized.
The complete formulation is presented below:
max
(∑
i∈RH
(y+i + y
−
i ) +
∑
i∈RL
y+i
)
s.t S.v = 0
vmin ≤ vi ≤ vmax
vi + y
+
i (vmin i − ǫ) ≥ vmin i i ∈ RH
vi + y
−
i (vmax i + ǫ) ≤ vmax i i ∈ RH
vmin i(1− y
+
i ) ≤ vi ≤ vmax i(1− y
+
i ) i ∈ RL
y+i , y
−
i ∈ [0, 1]
(2.5)
where v is the flux vector and S is a stoichiometric matrix, vmin and vmax are
lower and upper bounds of the fluxes, respectively, the boolean variables y+
and y− represent whether the reaction is active (in either direction) and the
ǫ value represent the minimum value that flux must have to for the reaction
is considered active.
This method relies on enzyme-expression data to infer tissue-specific
metabolic fluxes, thus it is not necessary to define an objective function
(biomass equation) and metabolites exchanged by the tissue with biofluids,
which indeed are unavailable for human tissues.
In [13], the validation of the predicted tissue-specific metabolic behaviour
uses biological information from Human Metabolome Database (HMDB) and
Braunschweig Enzyme Database (BRENDA). The metabolite exchanges that
depend on membrane transporters were validated based on data on tissue
specificity of transporters, obtained from the Human Membrane Transporter
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Database and from the Transport Classification Database.
The predicted tissue-specific metabolic behaviour was compared to various
data sources of genes, reactions and metabolites of each tissue type. For
the ten tissues, the predicted results were significantly correlated with data
sets, with the precision and recall varying between 0.36-0.7 and 0.37-0.55 [13],
respectively. The accuracy reflects the overlap between the predicted tissue-
associations of genes, reactions and metabolites and known tissue-associations
derived from various data sources.
2.5.2 GIMME
Also in 2008, another research group developed a new algorithm to gen-
erate context-specific metabolic models, the Gene Inactivity Moderated by
Metabolism and Expression (GIMME) [14].
This method uses gene expression combined with objective functions to
create functional metabolic models. However, as expression data is known
to be noisy, the results may vary depending on the methods used to convert
the fluorescence intensity to semi-quantitative readings of mRNA molecule
counts [93].
The GIMME algorithm takes three inputs: i) a set of gene expression data;
ii) the template genome-scale metabolic model; iii) one or more Required
Metabolic Functionalities (RMF) that the cell is known to perform.
Through the gene-protein-reaction rules, the algorithm uses the gene
expression data to determine which reactions are inactive or active in the
tissue. Reactions that correspond to expression levels below a specified
threshold, chosen by the user, are tentatively declared inactive unless they
are required for a desired functionality, according to a predefined objective
function. During this process, an inconsistency score (IS) is calculated and
represents the disagreement between the gene expression data and the flux
distribution for an objective function. The optimization problem tries to
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minimize the IS to produce a flux distribution with the minimal differences
to the expression data.
Therefore, the algorithm produces the flux distribution through a two-step
procedure:
1. Run a FBA for each RMF to find the maximum possible flux. The
RMFs represent metabolic tasks essential to the cell and the final result
must satisfy, such as the growth or the production of a target metabolite.
2. Solve the following linear programming problem:
min
∑
ci.|vi|
S.v = 0
ai < vi < bi
where ci =
{
cutoff − xi, cutoff > xi
0, otherwise
(2.6)
where xi is the normalized gene expression data mapped to each reaction
through the genes association present in the model; cutoff is the value
chosen by the user; S is the stoichiometric matrix; v is the flux vector;
ai and bi are the lower and upper bounds for each reaction. If a reaction
is one of the RMFs, the upper bound is set to the value found in step 1
(maximal value) and the lower bound to a fraction of its maximal value;
otherwise, the reaction is constrained with the bounds present in the
metabolic model.
The algorithm was used to describe the functional genome-scale metabolic
models for skeletal muscle cells in different conditions. The results obtained
for the human models were less interesting than expected, due the lack of
available data for a substantial number of human metabolic reactions [14].
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2.5.3 E-flux
The E-flux [15] method predicts the metabolic capacity based on expression
data. This method extends FBA [72] by incorporating gene expression data
into the metabolic flux constraints present in the formulation.
This approach starts by changing the reaction bounds present in the
metabolic model to integrate information from expression data. In short, if
the expression for a particular enzyme-coding gene is low, the upper bounds
of the reactions associated with this gene, will be replaced by a small value.
On the other hand, if expression is high, the new bounds will be similar to
the original ones. Once the constraint transformations are defined, FBA is
applied to determine a corresponding metabolic state or optimal metabolic
capacity.
E-Flux involves solving the following optimization problem:
max cTv
S.v = 0
ai ≤ vi ≤ bi
(2.7)
where v is a flux vector representing a reaction, S is the stoichiometric matrix,
c is a vector of weights indicating how much each reaction (v) contributes
to the objective function, and ai and bi are the lower and upper bounds of
reaction i.
In the original publication [15], this method was used to predict the impact
of drugs and environmental conditions on mycolic acid biosynthesis capacity
in Mycobacterium tuberculosis.
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2.6 Tissue-specific reconstruction methods
Recent studies have demonstrated that the metabolic profiles of tumor cells
most likely depend on genotype and the tissue of origin, and this has implica-
tions regarding the design of therapies targeting tumor metabolism [94].
Understanding the human metabolism of different cell types and the
interactions between them may lead us to determine efficient diagnosis and
treatment of these diseases. Thus, it becomes essential to develop metabolic
networks for distinct cell types/tissues.
During the last decade, some approaches have been developed to allow the
understanding of cell types metabolism. Shortly, these methods use a generic
human metabolic model as template, such Recon 1, and integrate omics data
from a tissue or context specific. As a result, some of them return a new
tissue-specific metabolic model, while others give also the flux distribution
that better represent the data used as input. In this section, the most relevant
methods will be presented.
2.6.1 MBA
A first approach has been proposed in 2010, named Model-Building Algorithm
(MBA) [16]. This algorithm reconstructs a tissue-specific metabolic model
from a generic model by integrating a variety of tissue-specific molecular data
sources (literature-based knowledge, transcriptomic, proteomic, metabolomic
and phenotypic data).
The first step of this algorithm is to infer, from the tissue-specific data,
two sets of reactions denoted as the core reactions (CH) and reactions that
have a moderate probability to be carried out in the specific tissue (CM).
This division is made according to the accuracy level of the input data. In
general, the CH set includes human-curated tissue-specific pathways and the
CM set includes reactions certified by molecular data.
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The aim of this method is to find the most parsimonious tissue-specific
consistent model, which includes all the tissue-specific high-probability reac-
tions (CH), a maximal number of moderate probability reactions (CM ) and a
set of additional reactions from the generic model that are required for gap
filling, using a greedy heuristic search that is based on iteratively pruning
reactions from the generic model (Figure 2.3). The full set of steps in this
method is shown in Algorithm 1.
 
Figure 2.3: The diagram illustrates the function of the model-building algo-
rithm (MBA). The algorithm is given tissue-specific reactions sets (CH and
CM) as input and reconstructs a tissue model containing all of the CH reac-
tions, as many as possible CM reactions, and a minimal set of other generic
model reactions that are required for obtaining overall model consistency.
To validate this approach a new metabolic model of liver was built from
the generic model Recon 1 [7]. The essential core, CH , was extracted from
literature-based curation, consisting in 37 intact metabolic pathways involving
779 reactions and 873 metabolites.The CM consisted of a set of 304 reactions,
and 484 metabolites and it was assembled from tissue-specific data sources,
including metabolomics, transcriptomics, proteomics, and phenotypic data of
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Algorithm 1 MBA algorithm pseudo code
function generateModel(RG, CH , CM)
RP ← RG
RS ← RP\(CH ∪ CM)
P ← randomPermutation(RS)
for (r ∈ P ) do
inactiveR← CheckModel(RP , r)
eH ← inactiveR ∩ CH
eM ← inactiveR ∩ CM
eX ← inactiveR\(CH ∪ CH)
if (|eH | == 0 AND |eM | < δ ∗ |eX |) then
RP ← RP\(eM ∪ eX)
end if
end for
return RP
end function
the liver. As a result of applying the algorithm, the liver metabolic model
consists of 1,827 reactions and 1,360 metabolites.
2.6.2 INIT and tINIT
The Integrative Network Inference for Tissues (INIT) algorithm was proposed
in 2012 by Jens Nielsen’s team [9]. The algorithm uses cell type specific
information from HPA as the main source of evidence for assessing the presence
or absence of metabolic enzymes in each of the human cell types. Moreover,
other data sources as tissue specific gene expression and metabolomics data
from HMDB are also used.
This algorithm requires a connected template human metabolic model as
input, so the first step was to provide a reliable and up to date genome-scale
model template. So, the Human Metabolic Reaction (HMR) database was
built with the elements of previously generic genome-scale human metabolic
models (Recon1, EHMM, HumanCyc), as well as with information from
KEGG database.
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The protein evidence levels retrieved from HPA or gene expression lev-
els from GEO datasets are converted to reaction scores through the GPR
associations present in the template model. The algorithm was formulated
as a MILP and tries to maximize the sum of scores for reactions that can
carry flux. According to the HMDB, the production of metabolites, known to
be present in the cell type, will be imposed by the formulation to ensure its
synthesis in the final model. Another detail in this formulation is the fact that
the steady-state conditions are not imposed allowing a small accumulation
of internal metabolites. This avoids the removal of reactions with dead end
metabolites.
The INIT formulation and can be specified as:
max
(∑
i∈R
wiyi +
∑
j∈M
xj
)
S.v = b
|vi| ≤ 1000yi
|vi|+ 1000(1− yi) ≥ ε
vi ≥ 0 i ∈ irreversible
bj ≤ 1000xi
bj + 1000(1− xi) ≥ ε
bj ≥ 0
xj = 1 j ∈ present
yi, xj ∈ 0, 1
(2.8)
where S is the stoichiometric matrix, v the vector of reaction rates, b a vector
of net accumulation or consumption rates for each internal metabolite, R
represents the reactions and M the metabolites. The parameter ε is an
arbitrarily small positive number and yi, xj correspond the active or inactive
state of a reaction and a metabolite respectively. The value of wi can be 20,
15, 10 or −8 to represent the high, medium, low and absent evidence levels
for proteins in the HPA. If the evidence comes from gene expression levels,
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wi is calculated as follows:
wi = 5 log
(
Signali,j
Averagei
)
(2.9)
The signal of gene i in tissue j is divided by the average signal across all the
tissues.
A couple of years later, a new version of INIT algorithm was proposed.
The Task-driven Integrative Network Inference for Tissues (tINIT) [20], which
reconstructs tissue-specific metabolic models based on protein evidence from
HPA and a set of metabolic tasks that the final context-specific model must
perform. These tasks are used to test the production or uptake of external
metabolites, but also the activation of pathways that occur in a specific
tissue. During the tasks validation in the template model, a set of required
reactions will be found and constraints to ensure the flux through these
reactions are added to the formulation. Another two improvements from the
previous version are the addition of constraints to guarantee that irreversible
reactions operate in one direction only and the possibility of choice whether
net production of all metabolites should be allowed.
2.6.3 mCADRE
Also in 2012, a new method was developed namedMetabolic Context specificity
Assessed by Deterministic Reaction Evaluation (mCADRE) [21]. This method
is able to infer a tissue-specific network based on gene expression data, network
topology and reaction confidence levels.
Based on the expression score, the reactions of the global model, used
as template, are ranked and separated in two sets: core and non-core. All
reactions with expression-based scores higher than a threshold value are
included in the core set, while the remaining reactions make the non-core set.
In this method, the expression scores do not represent the expression
levels, but rather the frequency of expressed states over several transcript
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profiles. Hence, it is necessary to initially binarize the expression data. Thus,
it is possible to use data retrieved from the Gene Expression Barcode (GEB)
project that already contains binary information on which genes are present
or not in a specific tissue/ cell type.
Reactions from the non-core set are ranked according to the expression
scores, connectivity-based scores and confidence level-based scores. Then,
sequentially, each reaction is removed and the consistency of the model is
tested. The elimination only occurs if the reaction does not prevent the
production of a key-metabolite, i.e. metabolites that have evidence to be
produced in the context-specific model reconstruction, and the core consistency
is preserved. The algorithm is provided below as Algorithm 2.
Algorithm 2 mCADRE algorithm pseudo code
function generateModel((RG, treshold))
RP ← RG
RC ← score(RP ) > treshold
coreActiveG← flux(r)! = 0, r ∈ RC
RNC ← RP\RC
for (r ∈ order(RNC)) do
inactiveR← CheckModel(RP , r)
s1 = |inactiveR ∩RC |
s2 = |inactiveR ∩RNC |
if (r 6∈ withExpressionV alues AND
s1\s2 <= RACIO AND
checkModelFunction(Rp\inactiveR)) then
RP ← RP\inactiveR
else
if (|s1| == 0 AND
checkModelFunction(Rp\inactiveR)) then
RP ← RP\inactiveR
end if
end if
end for
return RP
end function
Comparing with the MBA algorithm, mCADRE presents some improve-
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ments: allows the definition of key metabolites; some reactions of core set
can be removed from the final model; and, it is only necessary to run the
algorithm once, since the order of pruning the reactions is not random.
2.6.4 FASTCORE and FASTCOMICS
Also similar to MBA, the FASTCORE [22], proposed in 2014, is a generic
algorithm for context-specific metabolic models reconstruction that takes as
input a core set of reactions and a generic metabolic model.
Firstly, it converts the initial model to a consistency model, i.e. only
reactions that can carry flux in at least one feasible flux distribution are
preserved. This can be done by using existing approaches such as Flux
Variability Analysis (FVA) or a new one proposed in the work of Vlassis and
co-workers [22] for fast consistency check (FASTCC) of a network. Next, it
searches for a subnetwork from the generic model that contains all reactions
present in the core set and a minimal set of additional reactions, necessary to
guarantee the consistency of the final model.
Some advantages of this algorithm are that it can be applied to integrate
different kinds of ”omics” data through the core set compilation by the user,
and there is no need to define parameters except the flux threshold ǫ, which
is used to guarantee the required minimum flux.
Although the MBA and FASTCORE objectives are the same, that is ,
to find a minimal consistent model with all core reactions, the strategy is
significantly different. While MBA starts with all reactions and iteratively
prunes reactions from the generic model, FASTCORE iteratively expands the
active set A, starting with A = ∅.
The algorithm maintains a set, J ⊆ C, that is initialized with the irre-
versible reactions in C, and a ”penalty” set P = (N\C)\A that contains
all non-core reactions that have not been added to the set A. While not all
reactions from the core set are in the final model, the algorithm appends
the result of a function called findSparseMode to the set A. This function
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returns the set of reactions from the non-core set that maximizes the number
of reactions active from the set J . Formally, the algorithm can be described
as shown in Algorithm 3.
Algorithm 3 FASTCORE algorithm pseudo code
Let N the set of all reaction in the model, C the core set reaction and I
the set of irreversible reactions;
function FASTCORE(N,C)
J ← C ∩ I
flipped← False, singleton← False
A← findSparseMode(J, P, singleton)
J ← C\A
while J 6= ∅ do
P ← P\A
A← A ∪ findSparseMode(J, P, singleton)
if J ∩ A 6= ∅ then
J ← J\A, flipped← False
else
if flipped then flipped← False, singleton← True
else
flipped← True
if singleton then J˜ ← firstElement(J)
else
J˜ ← J
end if
for r ∈ J˜\I do
flip the sign in stoichiometric matrix
and swap the bounds of reaction r
end for
end if
end if
end while
end function
Based on FASTCORE, a new method has been proposed, also in 2014,
termed FASTCOMICS [95]. This method uses microarray expression data
to infer the core reactions used in the original method. Microarrays are the
most popular of the ’omics’ data sources, however the association with the
gene expression levels and active reactions is not trivial [82].
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FASTCOMICS is performed in two steps: generate the core set of reactions
based in transcriptomic data and reconstruct the context-specific metabolic
model using the FASTCORE algorithm. The first step of the FASTCOMICS
workflow is the discretization of microarray expression levels to build the core
set of reactions. The continuous expression values are converted to estimated
values of expressed (ones) and no-expressed(zeros) using the GEB algortithm
[96]. GEB uses the knowledge of abundantly publicly available microarray
data sets and the intensity distribution of each probe set, to classify the genes
as expressed or non-expressed (see Figure 2.4).
Figure 2.4: Conversion of gene expression levels to reaction scores. In the first
step, the gene expression values are converted to expressed / not expressed
status through the gene expression barcode method. Next, using the GPR
associations present in the model the score of each reaction is calculated.
The second step of the workflow, is the reconstruction of the context-
specific model through the FASTCORE algorithm and can be depicted in
Figure 2.5.
This workflow allows the definition of media constraints and forces the
biomass reaction to carry flux to find the required set of reactions that allow
the production of biomass.
This new set of reactions is then appended to the core set from the previous
step. Finally, a new run of FASTCORE, where all reactions from the core set
are forced to carry flux, is performed to find the context-specific model.
When comparing these two methods with other competing algorithms for
building of context-specific models like mCADRE [21], tINIT [9] or the MBA
[16], FASTCORE and FASTCOMICS reveal a higher performance. Depending
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Figure 2.5: FASTCOMICS workflow: first, the method runs to find the
required reactions to biomass production; next, an additional set of reactions
are joined and a second run is performed to build the final model.
on the generic model size, FASTCORE can generate the reconstruction of
context-specific GSMMs in a few minutes, whereas other algorithms would
take hours or days [22].
2.6.5 PRIME
Recently, the Personalized Reconstruction of Metabolic models (PRIME) [23]
method has been published, which utilizes both molecular and phenotypic
data to reconstruct context-specific GSMMs.
Similar to E-flux, the PRIME method tries to adjust the reaction bounds
according to the genes expression levels received as input. Nevertheless, some
differences have been introduced in this method, namely:
• the bounds of relevant reactions related with the genes that affect the
central cellular phenotype are changed;
• additional phenotypic data (growth rate) are used to establish the
relation between the gene expression levels and the flux rates and to
modify the bounds accordingly;
• modifies the flux bounds within a pre-defined range to avoid the differ-
ences between simulation and experimental growth rate.
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Similarly to other methods, PRIME takes as input a generic metabolic
model, ’omics’ and experimental data used to obtain the final model. In
this case, gene expression levels (transcriptomic data) and measurements of
growth rates are used.
The method workflow can be described in two steps:
1. find the set of genes that significantly correlate with the phenotype
(growth rate);
2. the upper bounds of reactions identified in (1) are modified according
to the expression levels.
However, PRIME has some limitations since it is based on the assumption
that all cells try to maximize their proliferation and depends on measurements
of a specific phenotype that in most cases are not available [23].
In this study [23], the authors have built more than 280 models for normal
and cancer cell-lines, utilizing them to predict drug targets that inhibit the
proliferation of cancer cells, but not the normal cells.
2.7 Conclusion
Several methods have been proposed to improve prediction of the phenotype
using omics data and to reconstruct metabolic models for a specific tissue or
context. The development of these methods has become possible thanks to
the increasing amount of high-throughput data available in the last decades.
Here, the main algorithms were presented, however, most of them are not
publicly implemented or their use is difficult for non-programmers. Thus, it is
crucial to develop an integrated framework to make these methods available
to all researchers.
Chapter 3
Development of Software Tools
This chapter describes the implementation options during
the development of the framework for the methods detailed
in the previous chapter. The development was made over
existing software that will be described here. The new de-
velopments regarding this work will be presented next, being
provided both a description of the implemented functionality
and the implementation technical details.
3.1 Introduction
In the last years, the increasing amount of high-throughput data available
allowed the surge of phenotype prediction methods, resorting to the integration
of transcriptomic and proteomic data [97], which can improve the accuracy
of metabolic model predictions. Generically, these methods can be divided
into two categories: the first encompassing methods where reaction fluxes
are considered on/off based on a cutoff expression level (including iMAT
and GIMME), and the second where the regulation of fluxes is based on
relative gene or protein expression (E-flux method). These methods have
been detailed in section 2.5.
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Furthermore, several tissue-specific metabolic model reconstruction meth-
ods have been proposed to deepen knowledge on specific contexts. These
methods, already detailed in section 2.6, also use trancriptomics and pro-
teomics as the main sources of input data.
However, until now, the usage of these methods has been limited to
developers or experienced bioinformaticians, since a platform that provides a
user friendly interface to perform such tasks is not available. Thus, in the
course of this work, a framework with the most relevant methods was developed
and integrated with an user-friendly open source software, OptFlux [24], a
reference tool that provides numerous tools for constraint-based modeling
tasks and metabolic engineering applications.
The developed framework is composed by an application programming
interface (API) for developers, who can use the provided library to extend
the available methods, and a graphical user interface (GUI), integrated into
OptFlux in the form of novel plug-ins, which encapsulates the developed tools
for non programming users.
The API layer provides three main features: loading and integrating
omics data with the metabolic model; simulating the metabolic phenotype
and reconstructing tissue-specific metabolic models methods using omics as
the main input (Figure 3.1). Some of the implemented methods also use
metabolic tasks to evaluate the reaction deletion effect over the reconstruction
process. Thus, it was also required to develop methods to import and validate
metabolic tasks.
This open-source API framework is available in SourceForge repository
(https://sourceforge.net/p/optflux/) within a project called mewomics-
integration. Users with computational skills are able to use the provided
library or contribute to its extension with new methods.
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Figure 3.1: Functional Modules developed in the Omics framework.
3.2 Metabolic Engineering Workbench
In this section, we describe the existing core libraries, which provided the
basis for the development of the libraries performed in this work.
The Metabolic Engineering Workbench (MEW) is a software framework
that supports in silico metabolic engineering tasks. This framework includes
nine libraries: mewcore, regulatorycore, biocomponents, biologicalnet-
score, guituilities, biovisualizercore, availablemodelsapi, solvers
and utilities, being the most relevant for this work discussed in detail in
the present section.
The framework is fully implemented in Java, an object-oriented program-
ming, platform independent and portable language. The execution of all
Linear Programming (LP) and Mixed-Integer Linear Programming (MILP)
optimization procedures uses GNU Linear Programming Kit (GLPK) [98].
Moreover, LibSBML [99] is used to handle files in the Systems Biology Markup
Language (SBML) [100] format. The main libraries and their classes are
detailed over the next subsections.
The main capabilities of the MEW framework can be grouped into four
distinct functional areas, as shown in Figure 3.2.
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Figure 3.2: Functional Modules present in the Metabolic Engineering Work-
bench framework.
3.2.1 The BioComponents library
The BioComponents library provides classes for reading and writing metabolic
models in several formats, such as SBML, Metatool [101], BioOpt/BioMet
[102], flat-files and a generic table format (coma/tab separated values).
Each of these file types can be read through the correspondent class from
package container.io.readers. Those classes implement the IContainer-
Builder interface, which guarantees the implementation of methods to retrieve
all necessary information to build an instance of the class Container. The
diagram of classes, including the main classes involved in the reading process
is depicted in Figure 3.3.
The Container class implements a constructor that takes an instance of
an implementation of IContainerBuilder as argument, which is used to pop-
ulate the instance object. The main class, Container, holds all information
related with the metabolic models: reactions, metabolites, genes, pathways
and additional information that can be used to integrate the entities from the
models with external databases, such as the Kyoto Encyclopedia of Genes and
Genomes database (KEGG) or the Chemical Entities of Biological Interest
database(ChEBI).
The information present in the class Container involves several other
classes used to store all the information, as:
• CompartmentCI: contains information about a cellular compartment,
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Figure 3.3: Main classes involved in the metabolic models reading process.
Each reader class implements the interface IContainerBuilder.
as the name, identifier and the list of metabolites.
• ReactionCI: contains information on a metabolic reaction, besides the
basic information (identifier, name, type, etc.), gene rules and proteins
rules are stored based on the GPR associations present in the model.
The products and reactants are stored in a map where the metabolite
identifier is the key and the stoichiometric coefficient is stored on an
instance of StoichiometryValueCI.
• MetaboliteCI: contains information about a metabolite, such as iden-
tifier, name, formula, etc. and a list of reaction identifiers where the
metabolite is a reactant or product.
• GeneCI: contains information about a gene, as the identifier, name and
the list of reactions that contain this gene in their GPR associations.
• ReactionConstraintsCI: class to store the lower and upper bounds
for a reaction flux.
The external information related with metabolites and reactions are saved
as a map of maps, with the structure Map <String, Map <String, String
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Figure 3.4: The Container class and its components used to store the
metabolic model information.
>>.The key of the external map is the information type and the key of the
internal map is composed of reaction or metabolite identifiers. For instance, for
saving information related with KEGG identifiers associated with metabolites,
the external info has the following structure:
["KEGG"--> [metaH2O –>C00001 ,
metaATP –>C00002,
... ,
metaala–>C19779]
]
The Container is the main class for the entire framework, since the
metabolic model it represents is the common base in all operations and
methods. This library also implements writing methods to save the content
of a Container in several formats, such as SBML, Metatool or CSV.
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3.2.2 The MEWCore library
MEWCore, as the name suggests, is the core library in the MEW framework. It
is responsible for the formulation of phenotype prediction methods, the strain
optimization procedures, the model simplification methods, the conversion
of model formats and for identifying critical genes/reactions. This library is
composed by several packages, which are detailed next.
The Model package
This package contains data structures to support all the information regarding
stoichiometric metabolic models. A stoichiometric model is composed by
metabolite and reaction sets and a matrix with the relation among these
entities through the stoichiometric coefficients present in each reaction. The
information related to pathways and GPR associations, when available, is
also integrated in the model data structure.
The SteadyStateModel is the main class used to store the stoichiometric
model information. This class aggregates information provided by other
classes, namely :
• IStoichiometricMatrix: this interface contains the abstract meth-
ods to manipulate the stoichiometric matrix .The class ColtSparse-
StoichiometricMatrix is usually used as an implementation of this
interface. This class contains the stoichiometric matrix, where each ele-
ment ai,j represents the coefficient of i
th metabolite on the jth reaction;
• Reaction: contains information about a reaction, including its name,
identifier, reversibility and flux bounds;
• Metabolite: contains information about a metabolite, including its
identifier, name, compartment as the main fields;
• Compartment: contains information related with the compartment,
such as name, identifier and the set of metabolite identifiers present in
that compartment;
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• Pathway: contains the metabolites and reactions sets present in a
specific pathway.
This class also allows the definition of basic model properties, such as the
name, model version and the biomass reaction (a particular reaction used to
represent cellular growth).
The SteadyStateGeneReactionModel class is an extension of Steady-
StateModel, where the information about genes, proteins and the GPR
associations is stored. The information present in both SteadyStateGene-
ReactionModel and Container classes is the same, but organized in a differ-
ent structure. The overall class diagram is depicted in Figure 3.5
Figure 3.5: Class diagram representing the structure of the classes used to
store the information of steady state metabolic models.
The data structure for the definition of environmental conditions, Environ-
mentalConditions class, is also contained in this package. It contains the
information about metabolite uptakes and reaction constraints used in the
phenotype prediction methods and in the strain optimization tasks. The
EnvironmentalConditions class contains an identifier that characterizes its
specific instance and a mapping data structure where the key, a reaction
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identifier, is mapped to a ReactionConstraint object, which contains the
lower and upper bounds of the reaction.
The Simulation package
The Simulation package contains the formulations for the phenotype simula-
tion methods. These methods allow the simulation of wild-type and mutant
strains using environmental conditions or gene/reaction knockouts.
In the current version, formulations such as the Flux Variance Analy-
sis (FVA)[103], Flux Balance Analysis (FBA)[2, 72], parsimonious enzyme
usage FBA (pFBA), Minimization of Metabolic Adjustment (MOMA)[73],
Regulatory on/off minimization of metabolic flux changes (ROOM)[74] and
Minimization of Metabolites Balance (MiMBl)[104] are implemented in this
package. Each one of these methods interacts with the Solver package (de-
scribed in Section 3.2.3) to solve the underlying linear or integer programming
problem.
One of the most important classes, the SteadyStateSimulationControl-
Center, is responsible for controlling and aggregating all features mentioned
above. The Figure 3.6 shows the main classes that interact with the Steady-
StateSimulationControlCenter.
The SteadyStateSimulationControlCenter receives the configuration
mapping object as an input. The configuration class contains properties, such
as the environmental conditions, the objective function used in the simulation
methods, the solver specification, the metabolic model, the simulation method,
among others. Moreover, the SteadyStateSimulationControlCenter has
also a static variable called factory, which holds the association between the
method name and the formulation class.
The formulation problem is instantiated in execution time, through the
SimulationMethodsFactory class. Using the factory method pattern in
the creation of the formulation problems avoids the replication of code and
simplifies the process of adding new simulation methods to the framework.
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Figure 3.6: Class diagram of the main classes involved in the phenotype
simulation on the MEW framework.
The interface ISteadyStateSimulationMethod defines the functions that
must be implemented by any formulation method. The interface IConvex-
SteadyStateSimulationMethod, an extension of the previous one, contains
the additional functions to support the persistent mode on the Solvers library.
The formulation classes are an extension of the abstract class Abstract-
SSBasicSimulation, which implements the interfaces referenced above, con-
taining the generic methods to interact with the Solvers library. When the
formulation problem contains a reference flux distribution, the Abstract-
SSReferenceSimulation should be used as the abstract class. Moreover, all
the classes must implement a method called simulation responsible to run
the formulation problem
At the end, the result of the simulate method present in SteadyStateSimu-
lationControlCenter, returns an instance of SimulationSteadyStateRe-
sult, which contains the flux distribution that represents the final phenotype
of the solution.
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The Figure 3.7 depicts the main steps in phenotype simulation using the
MEW classes.
Figure 3.7: The API layer highlighting the MewCore, BioComponents and
Solvers packages of the MEW framework for phenotype simulation.
The Simplification package
The Simplification package contains methods for model reduction and so-
lution simplification. The model reduction is an essential step used in the
optimization and simulation procedures to reduce search space by removing
reactions which cannot carry flux. This could be crucial to save memory and
improve performance when GSMMs are used for different tasks.
3.2.3 The Solvers library
The Solvers library provides several generic components (variables, constraints
and objectives) that can be combined to formulate any of the methods pre-
viously mentioned in the Simulation package from the MEWCore library.
Furthermore, the connection to open source and commercial solvers/opti-
mizers, including GLPK1, CLP2 and CPLEX3, is also provided through the
implemented classes such as GPLPKSolver, CLPLPSolver and CPLEXSolver.
1http://www.gnu.org/software/gplpk/gplpk.html
2https://projects.coin-or.org/Clp
3http://www-01.ibm.com/software/commerce/optimization/cplex-optimizer/
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Recently, this library has been extended to support a persistent mode which
allows keeping the problem formulation over several simulations, changing
only specific variables, constraints or objective functions as needed.
3.3 OptFlux framework
OptFlux [24] is a software framework to support in silico constraint-based
modeling approaches, mainly for metabolic engineering tasks, which aims to
be the reference platform for this community. The methods, algorithms and
features implemented on the MEW framework can be used by users without
any computer science skills through this user-friendly software tool.
OptFlux is a modular user friendly software based on a plug-in architecture
built on top of AIBench [105], which facilitates the addition of new features
by software developers. The main window of the application, shown in Figure
3.8, can be divided in three areas: the clipboard, the data viewing panels and
a logging area.
All objects created inside the application are associated to a global entity
named Project, which is always connected to a metabolic model. The user
can have multiple projects in the clipboard, however the input data to any
operation always belongs to the same project, as well as the corresponding
results.
The OptFlux framework is composed by several plug-ins, being the most
important:
• Core: responsible for creating the project, loading the metabolic mod-
els and creating the data types and views to manipulate the model
information, such as reactions, genes, metabolites, etc..
• Model Repository: adds a new model reader, which adds a repository
of validated models by OptFlux’s team.
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Figure 3.8: The OptFlux main window is segmented in three areas: 1 - the
clipboard, where the operations and results are showed; 2- the view area,
where objecta are visualized; 3- log window or memory monitor, depending
on the selected tab.
• Simulation: allows the user to perform phenotype simulation of ”wild-
type” and mutant strains, predicting the effects of knockout reactions
or genes or of over/under expression of genes or reactions.
• Optimization: includes single objective and multi-objective optimiza-
tion methods based on Evolutionary Algorithms and other optimization
approaches.
• Visualization: allows the user to visualize the model (or select path-
ways) in a graphical manner, also enabling users to import and export
layouts. Moreover, this plug-in allows the overlap of simulation results
with the model graphs [106].
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3.3.1 The AIBench framework
AIBench [105] is a software development framework, based on Model-View-
Controller (MVC) design pattern, that provides a powerful programming
model allowing the fast development of applications. The AIBench eases
the connection, execution and integration of operations with well defined
inputs/outputs. It facilitates the development of a wide range of applications
based on generic input-process-output cycles, where the framework acts as
the glue between each task.
The MVC design pattern divides a given software application into three
interconnected parts: model, controller and views. The idea is to make a clear
division between the objects that represent the problem (model) which are
controlled by operations, and the visualization of objects (views) that are the
GUI elements. Figure 3.9 depicts the MVC components and the interactions
between them.
Figure 3.9: A typical collaboration of the MVC components.
In the AIBench framework, these three types of well defined objects are
called: operations, data types and views.
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3.3.2 Data types
In Optflux, the data types are objects that hold relevant data to the ap-
plication, such as the models, simulation and optimization results, and are
usually an extension of the AbstractOptFluxDataType. Each plug-in has its
own datatypes normally present in the <<plug-in package>>.datatypes
package.
The datatypes classes within OptFlux, besides the object information,
also have a reference to the project to which the data belongs. Furthermore,
these classes are used to encapsulate the data structures present in the MEW
framework.
Considering that the metabolic model information in the MEW framework
is represented by an implementation of IModel, such as SteadySteateModel,
and the genes, reactions and metabolites by the classes Gene, Reaction
and Metabolite respectively, there are data types to encapsulate these data
structures. So, the classes SteadyStateModelBox, GeneBox, ReactionsBox
and MetaboliteBox are data types to encapsulates the MEW classes Steady-
SteateModel, Gene, Reaction and Metabolite.
3.3.3 Views
The views enable the output representation of information, being the way to
present the data types on appropriate GUIs (the same data types can have
more than one view to visualize their content). The association between data
types and the view used to show the information is made on the plugin.xml
file, available for each plug-in.
The Figure 3.10 presents several views for the model information datatypes.
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Figure 3.10: Views of the metabolic model information in the Opt-
Flux GUI: 1- MetabolicModelView, 2 - MetabolitesExternalView, 3-
textttReactionsInternalView and 4 -MatrixView, to visualize the content
of datatypes SteadyStateModelBox, MetabolitesBox, ReactionsBox and
StoichiometricMatrixBox, respectively.
3.3.4 Operations
The operations accept inputs in the form of objects from specific data types,
execute commands and generate new objects or update existing ones, from well
defined data types. The operations classes present in each plug-in are, in fact,
wrappers to execute the algorithms and procedures from the MEW library.
As an example, the operation NewProjectWizardOperation is responsible to
create a new project, with the correspondent metabolic model data types.
Based on the input files, the correct reader present in the MEWCore package
is called and an instance of the Container class is obtained. Next, the
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Container is converted to the ModelBox data type and inserted into the
clipboard. Moreover, some procedures, such as the biomass reaction definition
or the removal of external metabolites present in the model, can be done in
this operation.
Considering the “wild-type” phenotype simulation as another operation
example, the Figure 3.11 presents the main MVC components and their
interactions.
Figure 3.11: Scenario for an user interaction with the Simulation plug-
in. The three main MVC components are depicted: the user interacts
with the WildTypeSimulationGUI (a view) which invokes the WildType-
SimulationOperation (controller). The controller generates the Steady-
StateSimulationResultBox (model) which in turn updates the views.
3.4 Omics data integration
The methods for phenotype simulation and for reconstruction of tissue-specific
metabolic models require data as input that can be obtained from omics data,
such as transcriptomics, metabolomics, proteomics and/or fluxomics. Thus,
as a first step it was required the development of methods to import and
transform omics data, as well as to integrate them with the metabolic model.
The information loaded from omics data is stored on OmicsContainer
instances. This class contains the data characterization, saved as a Condition
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object (a map of < property, value >), a map with score values associated
with entities (genes, reaction or metabolites) and external information that
can be used to integrate the omics data with the metabolic model.
The reading and integration processes of omics is depicted in Figure 3.12
and encompass four main steps:
1. Loading: import the data from the original files to an OmicsContainer
object.
2. Data Filtering: allows the data filtering and identifiers format conver-
sion. This step is optional. The data filtering allows the data selection
by using regular expressions over fields of omics data. This can be used
to reduce the total amount of imported data and the time consumed.
The identifiers conversion is required when the nomenclature used in
the omics data and the model is not the same. In this case, it is neces-
sary to have an auxiliary external map ( < idmodel, idomics >) with the
conversion between nomenclatures.
3. Data Integration: the integration of omics data and the metabolic
model is done using associations between omics data fields and model
fields/associations. Usually, the association is done by the entities
identifiers. However, other properties from external information present
in the OmicsContainer or the entity name can be used. In the end,
an instance of the IOmicsDataMap class is obtained, where numerical
values associated with entities present in the model are stored (score
values).
4. Data Transformation: this step allows the application of functions
over the score values, such as logarithm transformation, conversion from
gene to reaction scores through the GPR associations present in the
metabolic model and scale the values to a specific range.
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Figure 3.12: Illustration of the data loading and integration processes.The
four main steps are: 1- to load original data to an OmicsContainer object; 2
- to apply transformation methods to reduce the total amount of data and/or
to convert the format of omics identifiers; 3 - to integrate the omics data with
the metabolic model; 4 - methods to transform the score values present in
the OmicsDataMap object.
3.4.1 Data loading
Different omics data sources can be loaded and used in the Omics framework.
At the moment, readers to specific file formats, such as metabolites data
files from HMDB and protein expression levels from HPA are supported.
Additionally, data present in CSV files can also be loaded through a generic
and flexible reader, named CSVOmicsReader. Using the generic CSV reader,
the user must specify the column indexes of the identifier and of the numer-
ical values. The other fields are imported as external information to the
OmicsContainer object.
The implemented Java classes from the Omics framework to load data
files to an OmicsContainer object are in omicsintegration.io package and
implement the interface IOmicsReader (Figure 3.13).
In the data reading process it is expected that the values associated with
each entity (metabolite, gene our reaction) are numerical. Otherwise, the
user must provide an additional mapping structure Map < String,Double >
to convert each discrete level to a numerical value. At the end, an instance of
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Figure 3.13: Classes involved in reading omics data. Only the main meth-
ods and variables are shown in the diagram. All readers implement the
IOmicsReader interface and its main method, load. As a result, is created
an instance of the OmicsConatiner class is created with the omics data in-
formation.
the class OmicsContainer is created.
The OmicsContainer class contains the essential information from the
omics data, mainly:
• condition: contains the information related to the description of the
condition/sample, such as the tissue name, the cell type, stage of disease
or any other properties used to characterize the data;
• type: identifies the omic data type: transcriptomics, fluxomics,
metabolomics or proteomics;
• values: a map with the structure Map < String,Double >, where the
key is the entity identifier and the value represents the gene/protein
expression level, the concentration of a metabolite, the reaction flux or
the presence/absent of the entity;
• extrainfo: a map with external information which can be used in the
integration with the metabolic model. For instance, when the identifiers
from the model and omics data do not follow the same nomenclature,
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it is necessary to have other fields, such as KEGG or ChEBI identifiers,
for metabolomics data, to allow the connection between the model and
omics data entities.
3.4.2 Integration with the metabolic model
The integration of omics data with the metabolic model has the objective of
setting the identifiers from OmicsContainer with the nomenclature used in
the metabolic model for the same entities (gene, reaction or metabolite).
This process takes as input an OmicsContainer object and converts it into
one of the following classes: GeneDataMap, ReactionDataMap, Metabolite-
DataMap. These classes implement the interface IOmicsDataMap and represent
transcriptomics, fluxomics and metabolomics data, respectively. Furthermore,
after the integration, only the identifiers present in the metabolic model are
retained in the omics data structure. Figure 3.14 shows the class diagram
with the main classes employed in the integration process.
Figure 3.14: Class diagram of main classes used in the integration of omics
data with the metabolic model.
Each omics data type has it own integrator class which is responsible for
implementing the convert method from the interface IOmicsIntegrator.
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The integration can be made through different information fields, such as
the identifier, the name or from external information data structures. Thus, if
the model integration field, modelIdField, contains the value ”ID” or ”NAME”,
the integration is made using the identifier or entity name from the metabolic
model, otherwise it is assumed that the field is present in the extra information
structure from the Container object. Similarly, the omics integration field,
omicIdField, specifies the used field from the OmicsContainer.
During the integration, it is possible to reach more than one value from
omics data for the same entity on the metabolic model. This happens, for
instance, if omics data identifiers come from transcript sequences instead of
genes, because several transcripts can be associated with the same gene. In
this case, the maximum value from the transcripts is assumed to be the score
value associated to the corresponding gene present in the metabolic model.
Another special case occurs when the same omics data entry (< id, value >)
is associated with more than one identifier in the model. Here, the omics
value is replicated for all matching entities from the metabolic model.
3.4.3 Transformation methods
There are two categories of omics transformation methods in the devel-
oped framework. The first contains methods over OmicsContainer ob-
jects to allow filtering data by using regular expressions over omics data
fields and to convert the identifiers to a new format based on a given map
with entries in the form: [oldid− > newid]. These two methods are imple-
mented in the omicsintegration.transform package under the class names:
TransformOmicsFilter and TransformOmicsKeys. All the transformation
classes applied to OmicsContainer objects must implement the interface
ITransformOmics.
The other contains transformations over the OmicsDataMap objects to
allow the values scaling or the conversion of gene to reaction scores under the
GPR associations. In the last method, the operators AND/OR present in the
GPR associations are, usually, replaced by the functions Minimum/Maximum.
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Thus, if a reaction is regulated by the gene rule ”gene1 and gene2” the reaction
score value will be the lower score among these genes. However, it is possible
to specify different functions to be applied in the transformation process.
The class FactoryTransformDataMap is responsible, in run time, to create
a transformation class instance based on the transformation type selected by
the user.
Figure 3.15: Diagram of classes implementing the transformation methods
available in the framework.
Following this class structure, it is easy to develop new transformation
methods, only being required the implementation of an interface method in
the ITransformDataMap class and the registration of the new transformation
class in the factory FactoryTransformDataMap.
3.5 Simulation methods
The simulation methods allow the phenotype prediction (flux values for the
reactions), using omics data to improve the results over traditional constraint-
based methods. The objective is to find a flux distribution, where an objective
function is defined considering the omics data as a guide for the distribution.
The three methods discussed in chapter 2, mainly the E-Flux, IMAT and
GIMME , are available in the omicsintegration.omicssimulation package
from the Omics framework.
The class diagram of the implemented algorithms and the connection to
the MEW classes are shown on Figure 3.16.
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Figure 3.16: Class diagram of simulation methods with omics integration.
All these methods are made available through the Omics plug-in discussed
in the following section 3.7. To simplify the instantiation of the methods,
a factory class was implemented, named FactoryOmicsSimulationMethods.
This class is responsible for returning the instance of the simulation class
according to the method chosen by the user in run time. This is used to avoid
the replication of code and to simplify the addition of new methods to the
framework.
In the implementation of these methods, we separate the omics data
processing from the algorithm. This means that all the algorithms accept as
input a ReactionDataMap as omics data source. The transformation from
gene to reaction scores is done using the methods presented in the previous
section. This separation in two layers allows to use several omics data sources
for each algorithm.
Each class implementing a simulation method is an extension of the class
AbstractSSBasicSimulation<T extends LPProblem>, which is responsible
for creating the simulation problem that will run in the solver.
The configuration to run each method is stored in a specific class: EFlux-
Configuration, IMATConfiguration and GIMMEConfiguration. All these
classes are extensions of the class GenericOmicsConfiguration, which con-
tains the basic information required to run phenotype simulation with omics
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data integration. In detail, this class has the metabolic model, the omics
data and the generic configuration properties, such as the solver type and the
environmental conditions to use in the phenotype prediction. Additionally,
the configuration class of each method has specific properties used by the
algorithm. The hierarchical structure of these classes is shown in Figure 3.17.
Figure 3.17: Class diagram for the configuration classes used in the phenotype
simulation methods of the Omics framework.
The constructor of each simulation method takes as input an instance of
the corresponding configuration class, since all the required information is
there.
3.5.1 iMAT
The IMATConfiguration class holds the configuration to run a phenotype
simulation using the iMAT algorithm, mainly up and down regulated reactions
sets used and the parameter ǫ value (with 1.0 by default).
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The iMAT algorithm is implemented in the class IMAT, where the extension
of the basic problem created by AbstractSSBasicSimulation is done. Here,
the methods createVariables, createConstrains and createObjective-
Function, are overridden to create the additional variables and constraints
for the iMAT formulation and to define the objective function.
3.5.2 GIMME
The GIMMEConfiguration class supports two different ways to get the limits
of reactions associated with the Required Metabolic Functionalities (RMFs)
in the GIMME algorithm:
1. by using a set of RMFs to constrain the reaction of each RMF to a
percentage of the maximum possible flux calculated by FBA. In this
case, the reaction limits for each RMF are calculated inside the GIMME
algorithm through the runRMFs function. The lower and upper bounds
are populated by a percentage of the maximum flux value obtained by
FBA and the flux value itself, respectively.
2. using a ReactionDataMap, which contains the maximum flux reaction
associated with the RMFs. The reaction lower bound is calculated
as a product of the maximum flux and the configuration property
RMF Percentage.
The GIMME algorithm class, GIMME, overrides the method createVaria-
bles where the constraints of RMFs associated reactions are changed to the
lower and upper bounds obtained by one of the previous described ways.
3.5.3 E-Flux
The E-Flux method is an extension of the FBA formulation being only re-
quired the update of the reaction constraints. These reactions constraints,
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given as argument to the method, are obtained by transforming the tran-
scpriptomic data ( scores associated to genes) to reaction scores through the
GPR associations.
In the class EFlux, the reaction scores received as input are normalized by
dividing each reaction score by the maximum of all scores. This normalization
converts all scores to values between 0 and 1. Next, the reaction constraints
are updated to set the lower and upper bounds to the normalized score.
Reactions without associated score in the input data will be constrained with
the upper bound of 1 and lower bound of -1, or 0 if the reaction is irreversible.
The external exchange reactions have the lower and uppers bounds as -1
and 1, respectively. However, when a reaction is only for uptake/secretion
the upper bound/lower is changed to 0.
3.6 Tissue-specific reconstruction methods
Besides phenotype prediction methods with omics data integration, the
framework also has methods to reconstruct tissue-specific metabolic models.
In summary, these methods use a generic model as template and evidences
provided by omics data and literature to reconstruct a context-specific model,
and were explored in detail in chapter 2, section 2.6.
In the framework, four methods were implemented: MBA, mCADRE,
tINIT and FASTCORE. Similarly to the simulation method’s classes, the
constructor receives a configuration object which contains all parameters and
data used by the algorithm. These four configuration classes were implemented
as an extension of GenericOmicsConfiguration.
Again, the layer of omics data processing is independent of the method
itself. Actually, all the methods expect a ReactionDataMap instance as main
input in the configuration object. Therefore, the processing of omics data and
conversion to a ReactionDataMap object is done using the methods presented
in section 3.4. This layer division allows us to use different omics data types
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with each implemented method.
Each one of the methods was implemented in a class, named from the
method’s name. These classes are an extension of the AbstractReconstruc-
tionAlgorithm which implements the interface ISpecificModelReconstruc-
tion. The hierarchical diagram of classes is depicted in Figure 3.18.
The result of the reconstruction process is an instance of the class
SpecificModelResult returned by the generateSpecificModel method
present in each class that implements a specific algorithm.
Figure 3.18: Class diagram of reconstruction of tissue-specific methods.
The assumptions taken during the implementation of reconstruction meth-
ods on this framework will be detailed in the next subsections.
3.6.1 tINIT
The tINIT method has two main steps: first, find out the set of essential
reactions to perform the metabolic tasks passed as input; second, simulate
the formulation problem described in section 2.6, which is implemented in
the tINIT class, where the reactions found in previous steps are constrained
to have flux.
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To perform the first step, additional methods were developed to load
metabolic tasks and find the reactions that can not be removed from the
model to be able to perform such tasks. The metabolic tasks can be loaded
by the TasksReader class from a CSV file with the following structure:
COM;ID;DESCRIPTION;SHOULD_FAIL;IN;IN_LB;IN_UB;OUT;OUT_LB;OUT_UB;EQU;EQU_LB;EQU_UB;OBJ_REAC
;id1; description;;M_A_e,M_B_c,M_C_e;-1000,-1000,-1000;0,0,0;M_Z_e;0;1000;;;;M_X_e
In the task above, the metabolic task id1, must produce the metabolite
M X, when the drains are open for the excretion of M Z and allowing uptake
of M A and M C. Moreover, it is assumed that metabolite M B can be
produced by the cell in the cytosol compartment.
This file can be constructed based on metabolite or reaction entities. The
entity references present in the file must be one of the following: identifiers,
names or any other field present in the external information from the template
model object, Container. However, the match between model entities and
tasks must be perfect, otherwise an exception will be thrown during the
reading process, telling that the metabolite/reaction does not exist in the
metabolic model.
The simulation of each metabolic model is done by the CheckTasks class.
First, the model is reduced to contain only the reactions that can carry flux.
Next, the drains present in the metabolic task are constrained to the values
present there, while the others are closed by setting the lower and upper
bounds to 0. Furthermore, for the internal metabolites, which are assumed to
have production, new artificial drains will be inserted in the model to uptake
such metabolites. In the previous example, a new drain to uptake M B c
will be added to the model.
Finally, an FBA with the maximization of the target metabolite, M X e,
is performed considering the changed model and the constraints imposed
to the drains reaction. Based on the result, we simulate the knockout of
each reaction that can carry, using FBA, to verify if the knockout reaction is
essential or not to satisfy the task. In the end, the set of essential reactions
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to satisfy the metabolic task is returned.
This set of reactions is afterwards used by the tINIT algorithm by adding
new constraints to the reconstruction problem, which guarantees that these
reactions must have a positive flux in the final result.
3.6.2 MBA
The MBA algorithm receives two reaction sets as input (CH and CM). Once
again, this information is given to the algorithm under a MBAConfiguration
instance. Ideally, the final tissue-specific model is built from a significant
number of models obtained by running several times the MBA algorithm.
Thus, after the construction of each model through the generateSpecific-
Model function present in the MBAAlgorithm class, the final model is created
through the static function getFinalModel. This function takes as input the
template metabolic model, the core reactions set and the path of all files with
the reaction identifiers of the tissue-specific models. At the end, a set with
the reaction identifiers present in the final consensus model are returned.
3.6.3 mCADRE
The mCADREConfiguration class contains the reaction scores, the confidence
levels and a set of metabolic tasks. These tasks contain the set of metabolites
that should be produced during the pruning process. This production is
checked on function checkModelFunction on the mCADRE class.
When the algorithm tries to remove a set of reactions from the model, the
production of essential metabolites is tested by adding a fake drain to the
model and a simulation is performed to check if the drain has flux excretion.
This simulation is done through the MinMax formulation problem, where the
objective function is the maximization of a constant value and the new drain
is constrained to carry a flux larger than 10−4. If the problem has a feasible
solution, then it is possible to have metabolite production in the model after
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the removal of a set of reactions. Alternatively, this step could be done using
the FBA with the maximization of the metabolite excretion, however this
would be time consuming.
3.6.4 FASTCORE
The FASTCORE algorithm was implemented using 3 main classes:
• FastCoreAlgorithm: this is the main class of the method and imple-
ments the algorithm presented in the Section 2.6.4;
• MaxNumberReactions: implements the LP formulation to find the
larger set of reactions from a given set with a positive flux rate;
• MinimizesFluxPenaltySet: implements the LP formulation to find
the smaller set of reactions with flux from the penalty set, when a given
set of reactions must have flux.
These two last classes implement the formulation problems, named LP7 and
LP10, respectively in the original paper [22]. Moreover, these classes are
an extension of the AbstractSSBasicSimulation<T extends LPProblem>
class from the MEW framework.
3.6.5 Running tissue-specific model reconstruction
In order to easily use the framework by non-programmers, a class to launch
the tissue-specific metabolic model reconstruction methods was implemented,
named GenerateModels. This class allows to run each method for different
omics data such as : HPA, GEB and two sets of reactions (core and moderate).
The configuration of all inputs required to build the tissue-specific models is
done through a text file where the following fields must be populated:
• ModelSBMLFile: path to the SBML template metabolic model;
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• BiomassReaction: biomass reaction identifier (null if no biomass
reaction exists on the model);
• HPAFile: path to a CSV data file with HPA protein expression levels.
This file must have two columns, the first with the gene identifiers and
the other with the expression levels;
• CHFile and CMFile: path to files with the core and moderate reac-
tion sets;
• BarcodeFile: file with the gene identifiers and the probability to be
active or not in the tissue. These data can be obtained from the GEB
website and must be converted to a map with the entities in the form
[GeneId− > score] using, for instance, the Bioconductor annotation
package;
• ConfLevelScores, TaskFile: information used in the tINIT method.
The task file must have the structure presented above (section 3.6.1),
where the header must have the same order and name fields;
• CellLine: identification of tissue , cell or context;
• convertGeneIdsFile: file to convert gene identifiers from omics data
to model format;
• ResultsPath: path where the final metabolic models will be stored;
• Method: one of the methods available in the framework. The field
must have the value “tINIT” , “mCADRE”, “MBA” or “FASTCORE”;
• OmicData: one of these omics data types: “HPA”, “Barcod”, “Sets”;
• CutOff1 and CutOff2: values to build the core and moderate sets.
The core set will be composed with reactions with a score higher than
CutOff1 and the moderate set encompasses the reactions with score
values between the two cut offs.
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• tINITCuttOff: values to use in the tINIT algorithm to create the five
expression levels.
Using this class to reconstruct the tissue-specific model there are some
rules that are assumed by the GenerateModel class, such as:
• The HPA expression levels, “High”, “Medium”, “Low” and “Not de-
tected” are always converted to the integer values 20, 15, 10 and −8,
respectively;
• The key metabolites used on mCADRE method are the same as pub-
lished in the original paper [21] as metabolites that should be produced
in all tissues cells.
3.7 Omics plug-in
The need to develop the software tools for regular users led us to design and
implement new plug-ins, to support the developments present in the previous
sections, within OptFlux, thus making the most of pre-existing tools. Thus,
two new plug-ins were created, the Omics and the OmicsSimulation plug-ins.
3.7.1 Implementation
The Omics plug-in was developed to support all the methods presented in
section 3.4 which include the reading, integration and the transformation
of omics data processes. Following the MVC design pattern, several new
components were created, from which the most relevant will be detailed.
The ImportOmicsWizard class and its related classes from the import-
omicswizard package, provide a set of dialogs for the ImportOmicsWizard-
Operation, which allows the user to load the omics data from data files and
perform some transformations over the original data, such as the conversion
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of entity identifiers and discrete levels to numerical values and the integration
with the metabolic model.
The addition of new readers is easily implemented. The new reader must
be an extension of the AbstractOmicsReader and implement the following
two methods:
• needsConfiguration: this function must return true if the reader
requires a specific configuration panel;
• getConfigurationPanel: returns the class which extends Abstract-
WizardConfigurationPanel and contains the specific configuration
panel.
After the reading process completes, the results are placed in the OptFlux
clipboard under the corresponding omics type folder (Gene, Reaction or
Metabolite). Moreover, the result can be an instance of one of the following
data types: GeneBox, MetaboliteBox or ReactionBox. All these classes are
an extension of the OmicsBox datatype, and its content can be visualized
through the OmicsView.
The omics data objects available in the clipboard can be used to ap-
ply a transformation over the score values or convert the gene scores to
reaction scores through the menu option Transform omics. Next, the GUI
TransformOmicsDataGUI is presented and the user can select the configura-
tion parameters required for the transformation. After the transformation
operation, TransformDataMapOperation, a new data object will be added to
the clipboard.
3.7.2 Functionalities
The steps to load a CSV file are shown in Figure 3.19. The step 2 only
appears when the data is imported from a generic CSV file.
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Figure 3.19: Dialogs to load and integrate omics data with the metabolic
model. 1- select the data source and set experiment properties such as tissue
and cell type. 2 - choose the identifier and values columns, other fields can be
imported as external information. 3 - convert the expression level to numeric
values; 4 - choose the fields that will be used to do the integration between
omics data and metabolic model. An additional conversion of identifiers can
also be set as an external file.
The view depicted in Figure 3.20 presents the experimental conditions to
help in data characterization and the score values associated to each entity
identifier, in this case the gene identifier.
3.8 Omics simulation plug-in
The simulation plug-in was developed to support the phenotype simulation
methods presented in Section 3.5.
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Figure 3.20: Omics data View.
3.8.1 Implementation
The configuration panel contains the parameters used in the configuration of
each algorithm. In iMAT, for instance, the user must set the ReactionOmics-
Box that will be used as input data, the lower and upper bounds used to build
the up and down regulated reaction sets. The reactions with score values
lower than the lower bound specified by user in the configuration panel, will
be considered down regulated by the algorithm. On the other hand, reaction
with scores higher than the upper bound will be considered upregulated.
The E-Flux does not require any additional information. Thus, it is not
necessary any configuration panel for this method.
The GIMME configuration panel, GIMMEConfigurationPanel, accepts
two ways to limit the RMF’s flux reactions: a list of reactions scores, a
ReactionOmicsBox datatype, where each score represents the maximum flux
for a reaction, or a list of metabolic tasks used to calculate the maximum flux
for the objective function, a reaction, of each metabolic task.
Additional fields are required to run this method, such as:
• Percentage: this value is used to constrain the RMF’s objective in
the formulation. These reactions which represent the RMFs must have
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a flux higher than a percentage of the maximum possible flux.
• Cutoff: is a threshold value set by the user above which a reaction is
considered to be present.
3.8.2 Functionalities
The OmicsSimulationGUI provides a dialog for the OmicsSimulationOpera-
tion, which allows the user to configure and launch a strain simulation with
omics integration procedure. This dialog is depicted in Figure 3.21.
Figure 3.21: Screenshot of the simulation methods configuration dialog.
This GUI allows setting up and configuring several optimization parame-
ters:
• Select Project: select the metabolic model associated to the project
to perform the simulation;
• Select Environmental Conditions: the list of available environmen-
tal conditions for this project.
• Select Omics Data: select the instance of ReactionOmisBox datatype
used as input. Only this data type is available, because all the available
methods use ReactionDataMap object as input;
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• Select Simulation Method the method used to perform the simula-
tion;
• Configuration Panel: this panel depends of the selected method.
Each method has it own panel with the required configuration fields
(IMATConfigurationPanel, IGIMMEConfigurationPanel, EFluxConfi-
gurationPanel). All these classes are an extension of the abstract class
AbstractOmicsSimulationConfigurationPanel.
3.9 Conclusion
This work proposes an integrated framework to use omics information in
phenotype predictions and to reconstruct tissue-specific metabolic models.
The development is segmented in two layers allowing both users with compu-
tational skills and regular users to use the methods implemented during this
thesis. Moreover, the addition of new features and new methods can be done
easily by programmers using the provided API.
The addition of two new plug-ins to integrate omics data with models
and phenotype prediction in the open-source OptFlux platform makes it an
attractive resource to an ever increasing community.
The described software was developed in the Java programming language,
and is available as an open source packages (mewomicsintegration and
optflux-omicsintegration) in sourceforge.net/p/optflux/. Moreover,
a docker container is available in the repository https://hub.docker.com/r/
saracorreia/tsmm U251 which allows the reconstruction of tissue-specific
metabolic models for the U-251 cells line (further described in Chapter 6).
Future work contemplates the development of a new plug-in to support a
graphical user interface for the tissue-specific reconstruction methods.
Chapter 4
Evaluating Phenotype
Simulation Methods
In this chapter, a validation of the phenotype simulation
methods implemented in this work was performed, using
omics datasets from a previous study. The three imple-
mented methods: E-Flux, GIMME and iMAT were used to
perform phenotype prediction and their flux distributions
were compared with the experimental data provided in this
study.
4.1 Introduction
The nicotinamide adenine dinucleotide (NADH) and the adenosine triphos-
phate (ATP) cofactors play an important role in metabolism. NAD is involved
in redox reactions, carrying electrons from one reaction to another and the
ATP is the source of energy to several biological processes that occur in the
cell [107]. These cofactors, NADH and ATP, are highly connected in the
metabolic networks of most microorganisms [108]. Thus, it is expectable that
small changes in their concentration causes significant modifications in several
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parts of the metabolism.
In 2010, Holm et al. [109] studied the impact of these two cofactors in
the Escherichia coli metabolism regulation. More specifically, the authors
wanted to understand aspects of metabolism that are controlled by the levels
of NADH or ATP present in the cell. In the study [109], they compared the
phenotype of the wild-type strain and two mutants: NOX (overexpression
of NADH oxidase) and ATPase (overexpression of soluble F1-ATPase). The
analysis was done based on the quantification of the metabolic fluxes in central
carbon metabolism and the genome-wide transcription for the three E. coli
strains.
4.2 Methods
As a case study, this dataset was used to evaluate the implemented phenotype
simulation methods: E-flux, GIMME and iMAT. The dataset is composed
by transcriptomic and 13C-flux data for the three E .coli strains. The tran-
scriptomic data can be obtained from the NCBI Gene Expression Omnibus
using the accession number GSE20374 and metabolic flux measurements are
available in the supplemental material of the publication [109].
The implemented simulation methods were applied using the genome-scale
metabolic model iAF1260 [110] to predict the phenotype and considering
the gene expression data as input . In all simulations, the glucose uptake
constraint present in the original model was overridden with the experimental
value for each strain present in the dataset. Thus, for the simulation of
each E .coli strain, the limit of the glucose uptake present in Table 4.1 was
considered:
Table 4.1: The glucose uptake rate constraint for each E. coli strain.
Wild type NOX ATPase
Glucose 9.2 11.7 15.6
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4.2.1 Pre-processing the fluxomics data
Following a suggestion from [111], the experimental data values were adjusted
to the feasible flux distributions obtained with the metabolic model, with
the smallest Euclidean distance to the original values. This modification
is desirable because some of the experimental values do not lie within the
solution space, being the error propagated to the methods evaluation. Table
4.2 contains the original flux values measured by 13C-labeling and the value
after the adjustment, used in this case study for methods evaluation purposes.
Table 4.2: Original measured values and the adjusted values obtained by the
closer feasible flux distribution using the metabolic model iAF1260.
Original Adjusted
Reaction WT NOX ATPase WT NOX ATPase
Ec biomass 0.67 0.63 0.58 0.47 0.49 0.39
FUM 1.6 4.8 4.3 1.67 4.84 4.36
G6PDH2r 4.4 4.9 5.1 4.40 4.90 5.10
GAPD 15.3 20.4 28.3 15.31 20.41 28.31
GLCptspp 9.2 11.7 15.6 9.20 11.70 15.60
GND 4.4 4.9 5.1 4.40 4.90 5.10
ICDHyr 2.5 5.6 5.1 2.43 5.56 5.04
ME1 0 0.2 0 0 0.16 0
PGK −15.3 −20.4 −28.3 −15.31 −20.41 −28.31
PGL 4.4 4.9 5.1 4.40 4.90 5.10
PPC 4 4 6.5 4.07 4.04 6.56
PPCK 2 1.8 4.8 1.93 1.76 4.74
RPE 2.4 2.8 3 2.39 2.80 2.99
RPI −2 −2.1 −2.1 −1.99 −2.08 −2.09
TALA 1.3 1.5 1.6 1.30 1.51 1.61
TKT1 1.3 1.5 1.6 1.30 1.51 1.61
TKT2 1.1 1.3 1.4 1.09 1.29 1.39
TPI 7.1 9.6 13.5 7.06 9.52 13.43
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4.2.2 E-Flux
The implementation of E-flux, described in section 2.5.3, is basically an
extension of the FBA problem, where the fluxes are constrained based on
trascriptomic data. The score value of each reaction is calculated based on
the GPR association, where the OR / AND operators are converted to Max /
Plus functions as described in the original publication [15]. These scores are
then normalized causing each reaction, rj, to be constrained with an upper
bound bj, between 0 to 1, and a lower bound equal to −bi or 0, when the
reaction is irreversible. Furthermore, all uptake reactions are constrained to
a lower bound of −1. The resulting flux distribution is adimensional. Thus,
to compare it with the original flux distribution, the values were scaled by
the experimental measured glucose uptake rates.
4.2.3 GIMME
The GIMME method, detailed in section 2.5.2, besides the transcriptomic
data, receives three parameters as argument:
1. the gene expression cutoff, which was set to the 25th percentile of the
gene expression values;
2. the metabolic function that represent the Required Metabolic Function-
ality - in this case, the maximization of biomass production;
3. the required fraction of the objective value, which was set to 90% of
the maximum growth rate.
For each strain, according to the description in section 2.5.2, a FBA was
performed to find the maximum possible flux rate of the biomass equation.
Next, the algorithm was run with a constraint over this reaction flux which
must be at least 90% of the maximum flux.
4.3 Results 77
4.2.4 iMAT
The iMAT (section 2.5.1) implementation also takes three parameters as input:
the low and high expression thresholds used to calculate the up and down
regulated reactions, and a threshold which was set to 1, as in the original
publication [13]. The two expression thresholds were set to the 25th and 75th
percentiles of the experimental flux data. The reactions with score lower than
the 25th percentile were considered downregulated, while scores higher than
the 75th percentile belong to upregulated reactions.
The Table 4.3 presents the threshold values used in each strain phenotype
prediction by GIMME and iMAT methods.
Table 4.3: The 25th and 75th percentiles of the experimental flux data from
each strain used as thresholds by GIMME and iMAT methods.
Strain 25th percentile 75th percentile
Wild type 8.12 11.41
NOX 8.95 11.27
ATPase 8.58 11.25
4.3 Results
The phenotype prediction, using the implemented methods, was done for
the three E. coli strains using the transcriptomic data available from [109].
The GIMME and iMAT methods were previously available in the COBRA
Toolbox. Moreover, this dataset was already used to compare and evaluate
the results of several methods in Machado et al. [111].
Here, the prediction capability of each implemented method in our frame-
work is compared with the experimental data [109] and the previous work
[111] with the same datasets.
Figure 4.1 shows the secretion flux rates for the two available external
experimental measurements in the dataset.
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Figure 4.1: Predicted and measured flux rates for acetate secretion and growth
for the three E. coli strains using the methods E-Flux, GIMME and iMAT.
The secretion of acetate is reached in all phenotype predictions. However,
none of the algorithms are able to show the decreasing flux rate between the
wild type and the NOX strain, as shown in the Figure 4.1 A). Regarding the
growth rate prediction, E-flux and GIMME are capable to predict cellular
growth. However, once again, the small decreasing flux rates in the ATPase
strain are not shown by the predicted values.
These results are significantly different from those presented in [111],
where the phenotype prediction for the two mutants (NOX and ATPase) were
analyzed. In their study, none of the methods presented secretion rates for
acetate and only the E-Flux is able to predict growth.
4.3 Results 79
4.3.1 Prediction error
In order to evaluate the prediction capability of the methods, the flux dis-
tributions obtained using transcriptomic data from three E. coli strains are
compared against the adjusted experimental measured fluxes.
Figure 4.2 shows the distribution of the normalized prediction error for
each method across the three strains (wild-type, NOX and ATPase). The flux
distribution errors were compared with the error obtained using the pFBA
(parsimonious version of FBA) method for the phenotype predictions.
Figure 4.2: Prediction error for the simulation methods. Distribution of
normalized prediction error for the methods E-Flux, GIMME, IMAT, pFBA.
The normalized prediction error was calculated for each simulation, com-
paring its results with the adjusted experimental values. The estimation error
is given by the equation:
error =
‖vexp − vsim‖
‖vexp‖
(4.1)
where vexp is the vector of adjusted flux values and vsim is the vector of
predicted values.
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Similarly as concluded in [111], the three methods have a lower predictive
capability, when compared with the pFBA. However, in our results the iMAT
present a significant improvement, comparing with the results obtained in
[111] are considered.
Next, to better understand how the distribution error varies accross the
measured flux reactions, a heatmap of the differences between the predicted
and measured fluxes is presented in Figure 4.3.
Figure 4.3: Difference between predicted and measured fluxes for all evaluated
methods across all E. coli strains.
Looking to the prediction errors for a specific strain, it is visible that
the GIMME and pFBA methods have similar error distributions across the
presented reactions. Moreover, considering the wild type strain, the E-Flux
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method has a better prediction for reactions where other methods fail, such
as: ACONTa, CS, and AKGDH.
4.3.2 Central carbon metabolism
The experimental measured fluxes belong to the central carbon metabolism
of E. coli. In order to analyse the flux distribution over these reactions and
compare it to the predicted flux distributions, Figure 4.4 presents the main
reactions involved and the flux distributions for the wild type strain.
Analysing these flux distributions, it is visible that some reactions carry
flux in the opposite direction when compared with the measured fluxes, such
as the R PGI reaction for the iMAT flux distribution and the R TKT1 and
the R TKT2 reactions in the E-flux.
The conversion of PEP to Pyruvate is essentially done through the R -
GLCptspp, instead of the emphR PYK reaction. Moreover, the E-Flux distri-
bution has an alternative pathway, not seen in this image, to convert Pyruvate
into acetyl-CoA, since the reaction R CS from the TCA cycle has flux.
Finally, the flux rates associated with the reaction R ACKr confirm the
acetate production in the predictions.
4.4 Conclusion
In this chapter, a validation of the implemented simulation methods was
performed, comparing our results with previous published work [111]. The
two studies use the same E. coli metabolic model and transcriptomics data to
perform phenotype prediction, using E-Flux, GIMME and iMAT as simulation
methods. Next, the 13C flux measurements from [109] were used to evaluate
the capability prediction of such methods .
In general, our results are similar with the published results. In both
cases, the phenotype predictions using pFBA have a lower prediction error
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associated. This can be explained by the low number of measured reactions,
only 36 of the 2382 present in the metabolic model iAF1260.
The main difference between the two studies is found in the secretion of
acetate. In [111], none of the predicted flux distributions have secretion of
acetate, but in our results the acetate production occurs. This difference might
be explained since the methods allow different flux distributions achieving
optimal values for the objective function.
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Figure 4.4: Metabolic flux distribution in the central carbon metabolism of E.
coli wild type strain, of experimental data (black), and using the simulation
methods: E-Flux (red), GIMME (green) and iMAT(blue).

Chapter 5
Evaluating Tissue-Specific
Model Reconstruction
Algorithms and Data Sources
This chapter presents the comparison and analysis of the
consistency between several omics data sources. More-
over, four published approaches were used to reconstruct
hepatocytes metabolic models using different omics data.
These models were compared and validated through a list
of metabolic tasks, which hepatocytes cell must perform.
Finally, based on the results, a method to build a consensus
final model is proposed to generate our final hepatocytes
metabolic model.
5.1 Introduction
In chapter 2, we presented methods for integrating genome-scale metabolic
models with omics data, which can be separated in two categories. The
first one encompasses all the methods that use these data to improve the
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prediction of metabolic flux distributions, such as iMAT, GIMME and E-
Flux. These methods have been already critically evaluated and compared
in published work by Machado et al [111] and in the previous chapter. The
other category covers the context-specific reconstruction methods which use
generic metabolic models and omics data as input. Here, we include methods
such as MBA [16], mCADRE [21], tINIT [20] and FASTCORE [22].
Recently, two categories of approaches have been proposed to test model
building algorithms [112]. The first encompasses tests for assessing the
algorithms robustness against noise, while the second covers the comparison
of a set of functionalities that models are able to perform, using published
data as reference. However, these tests were done using a single omics data
type as input, which does not allow the analyses of the effects of input data
in final models behaviour. Moreover, important methods such as tINIT,
mCADRE and MBA were not considered in validation process.
Thus, the impact of using different omics datasets on the final results of
those algorithms is a question that remains to be answered.
5.2 Methods
The human liver is one of the most important organs in the regulation of
the human metabolism, being responsible for numerous functions, as the
production of bile, removal of toxic substances, decomposition of red cells and
chemical regulation of the plasma [113]. The liver consists in different types of
cells: parenchymal cells (hepatocytes and bile duct cells) and nonparenchymal
cells. Disorders in the metabolism of distinct cell types cause a number
of diseases, like hepatitis, nonalcoholic fatty liver disease or hepatocellular
carcinoma (HCC) [114]. HCC strikes about half a million humans in the
world and it is the most usual form of primary cancer [115].
The analysis of the differences at a molecular level of healthy and disease
states, made possible by the enhanced high throughput technologies and
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decreasing costs of obtaining different omics data, can help to clarify the
functional mechanisms of liver cells and related diseases [116].
About 78% of the liver tissue is formed by hepatocyte cells that are the
principal site of the metabolic conversions underlying the diverse physiological
functions of the liver [117]. To have a better understanding of how hepatocyte
cells work, different algorithms have been applied to reconstruct tissue specific
metabolic models for this cell type [16, 21]. Also, Gille et al. built a manually
curated GSMM for hepatocytes, the HepatoNet1 [17].
Here, hepatocytes metabolic models were reconstructed using different
omics data sources and different algorithms, to evaluate the effects that each
of those variables have in the resulting tissue-specific metabolic models and
their behavior.
5.2.1 Generic human metabolic models
At the time of this work, three generic genome-scale human metabolic mod-
els and a reaction database used to reconstruct tissue-specific models were
available [7, 8, 10, 62].
An analysis of the most used generic human metabolic models [7, 10, 62]
in the reconstruction of tissue-specific models was performed to highlight
the main differences between them. This was done using an integration
system developed in our research group by Liu et al. (unpublished). The
reaction and metabolites are unified in a Neo4j graph database [118], where
information present in the models such as KEGG and ChEBI identifiers,
chemical formulas and names are used to integrate metabolites into clusters.
The integration of reactions was done using these clusters and assuming that
reactions from different models are the same if they have the same metabolites
(i.e. metabolites joined in the same clusters) as reagents and products.
During the integration process, the presence of protons in the reactions was
ignored. So, if two reactions from a model differ only in the presence/absence
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of protons they will be considered the same reaction. This assumption is only
made for the overlap analysis of generic metabolic models.
In the present analysis, the drain reactions were not considered. Therefore,
the metabolic models Recon 1, Recon 2 and HMR 2.0 have 3.207, 6.462 and
6.896 unique reactions, respectively.
The overlap between models is shown in Figure 5.1. As expected, the
Recon 2 has almost all reactions present in Recon 1, its previous version.
Figure 5.1: Number of integrated reactions across the three main generic
human metabolic models - Recon 1, Recon 2 and HMR 2.0.
Being the HMR2.0 constructed by integrating the elements of stoichiomet-
ric networks of human metabolism, namely Recon1, the Edinburgh Human
Metabolic Model and the KEGG database [62], it was expected a better
consensus between the two analysed models (Recon 1 and HMR2.0).
Next, the analysis of which pathways are associated with the non integrated
reactions was done using the subsystem information present in the models
(loaded from their SBML files). The differences between Recon1 and Recon2
are essentially related with fatty acid synthesis and oxidation pathways (248
reactions) and transport reactions between compartments (544 reactions).
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The comparison between Recon 2 and HMR2.0 is more difficult to make, since
the pathway identifiers are different and in some cases a single pathway in
one model is split in more than one pathway in the other. Moreover, 967
non integrated reactions from HMR2.0 do not have information about their
subsystem. Nevertheless, the reactions not integrated between the two models
belong essentially to the pathways: Glycerolipid metabolism, Formation and
hydrolysis of cholesterol esters, Glycerophospholipid metabolism, Carnitine
shuttle, Sphingolipid metabolism, Leukotriene metabolism, Phenylalanine,
tyrosine and tryptophan biosynthesis.
The difficulty of model integration and the poor overlap between them
was already discussed in 2011 by Stobbe et al. [119]. The standardization of
metabolite names and identifiers and the manual curation are still required
to improve and develop an unified and biologically accurate metabolic model.
5.2.2 Reference metabolic model
In 2010, a genome-scale metabolic network of human hepatocytes was pre-
sented by Gille et al, the HepatoNet1 [17]. This network enables the ap-
plication of constraint-based modeling techniques to discriminate allowable
metabolic states in hepatocytes in different environmental conditions. The
initial list of reactions to consider to establish a stoichiometric model of
human hepatocyte metabolism was obtained from the two existing global
reconstructions of the human metabolic network - Recon 1 and EHMN, and
from the KEGG database. Moreover, databases like BRENDA, Reactome
and UniProtKB were used for validation proposes [17].
The resulting metabolic network satisfies 442 different metabolic objectives,
related to known metabolic liver functions, and guarantees that impossible
tasks are not achievable within the network. Furthermore, the final metabolic
model comprises 777 metabolites in six intracellular and two extracellular
compartments and 2.539 reactions, including 1.466 transport reactions.
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5.2.3 Input data sources
All the context-specific reconstruction methods used take as input a generic
metabolic model and information from omics data. The omics data used for
the reconstruction of the hepatocytes metabolic models were obtained from
proteomics and transcriptomics. Manually curated sets of reactions used in
[16], to reconstruct the hepatocytes metabolic model, were considered.
Proteomics data were retrieved from the Human Protein Atlas (HPA) [84],
which contains the profiles of human proteins in all major human healthy and
cancer cells. The information was collected for the liver tissue (hepatocytes)
from HPA version 12 and Ensembl [120] version 73.37. After a conversion
from Ensembl gene identifiers to gene symbols, duplicated genes with different
evidence levels were removed. Table 5.1 presents the list of removed genes
during this process.
Table 5.1: Gene symbols with different evidence levels in Human Protein
Atlas.
Ensembl ID Expression Level Gene Symbol
ENSG00000169894 Medium MUC3A
ENSG00000228273 High MUC3A
ENSG00000115540 Low MOB4
ENSG00000270757 Medium MOB4
ENSG00000123444 Not detected KBTBD4
ENSG00000231880 High KBTBD4
ENSG00000080200 Not detected CRYBG3
ENSG00000233280 High CRYBG3
ENSG00000243649 Low CFB
ENSG00000244255 Medium CFB
ENSG00000181464 Medium CDRT1
ENSG00000241322 High CDRT1
ENSG00000169894 Medium MUC3A
Transcriptomics data were collected from the Gene Expression Barcode
(GEB) [96] (HGU133plus2 (Human) cells v3). The conversion to gene expres-
sion levels was done considering the average level of probe sets for each gene.
The mapping between probe sets and gene symbols was performed using
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the library “hgu133plus2.db” [121] from Bioconductor [122]. Bioconductor
provides tools for the analysis of high-throughput genomic data, using the R
statistical programming language. In the version 3.2, Bioconductor contains
1104 software packages, 257 experiment data packages, and 917 annotation
packages.
The context-specific reconstruction methods, chosen for this work, use
different formats of input data. Specifically, MBA uses two sets of reactions,
where each reaction has High or Moderate probability to be in the final model,
while mCADRE and FASTCORE expect only one set of reactions as input.
In the tINIT method, each reaction from the generic metabolic model must
have a score value of 20, 15, 10, −8 representing the High, Moderate, Low
or Not detected evidence of protein expression levels respectively. A default
value of −2 is used for reactions without information in input data. The
Table 5.2 summarizes the input data type supported by each algorithm.
Table 5.2: Required and optional input data for each algorithm.
Required Optional
MBA Two reaction sets
(high and moderate
probability)
tINIT Reaction scores Set of required reac-
tions calculated based
on a set of metabolic
tasks. Set of metabo-
lites that final model
must produce
mCADRE One reaction set (core) Set of metabolites that
must be produced in
the final model
FASTCORE One reaction set (core)
These input data diversity leads to the requirement of data transformation,
in order to allow its use in different methods. The continuous data from GEB
was classified as High, Moderate and Low, if the gene expression evidence on
that tissue is greater than 0.9, between 0.5 and 0.9, and between 0.1 and 0.5,
92 Evaluating TSM Reconstruction Algorithms and Data
respectively. The genes with expression evidence below 0.1 were considered
not expressed in hepatocytes. The core reaction sets used in mCADRE
and FASTCORE methods were built considering the union of “High” and
“Moderate” gene evidences from HPA, or gene expression evidence greater
than or equal to 0.5 from GEB, through the GPR association present in the
template model.
The Table 5.3 summarizes the assumptions used to create the input data
sets for each algorithm.
Table 5.3: The table summarizes the assumptions and thresholds used to
create the sets used as input by the algorithms.
Algorithm input CH, CM HPA GEB
MBA
CH CH High [0.9, 1.0]
CM CM Moderate [0.5, 0.9[
tINIT
High CH High [0.9, 1.0]
Moderate CM Moderate [0.5, 0.9[
Low Low [0.1, 0.5[
Not detecetd Not detected [0.0, 0.1[
mCADRE core CH ∪ CM High ∪ Moderate [0.5, 1.0]
FASTCORE core CH ∪ CM High ∪ Moderate [0.5, 1.0]
Applying these transformation rules is possible to adapt different input
data sources, such as HPA, GEB and CH and CM sets, for all methods.
5.2.4 Reconstruction workflow
A framework with the four tissue-specific metabolic models reconstruction
methods was implemented as described in chapter 2. All the algorithms in
this framework were adjusted to receive a reaction scores map as main input.
Nevertheless, some methods such as mCADRE and tINIT, still allow the use
of a set of metabolites which must be produced in the final model.
Therefore, the algorithms are made independent from the omics data
source, and the separation of these two layers allows to use different data
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sources combined with each algorithm for the generation of tissue-specific
metabolic models.
Generically, the hepatocytes metabolic models reconstruction process had
four main steps:
1. First, it was necessary to collect the data from HPA and GEB reposi-
tories. The Ensembl gene identifiers present in HPA information were
converted to gene symbols to allow the integration with the template
metabolic model - Recon 1. A similar transformation was required to
convert the GEB information, where the original expression level is
associated with probe sets. The reaction sets CH and CM from [16] are
already at the reaction scores level, so the current and next steps were
not required.
2. Based on the data from previous step, it was required to convert the gene
scores to reaction scores. This was performed through GPR associations
present in the template model by the substitution of AND/OR operators
by the Min/Max functions. If one of the gene scores is unknown, its
value was ignored in the GPR association.
3. Next, the final core reaction sets were built based on the assumptions
described in Table 5.3. In this step, some additional configurations
were required depending on the selected algorithm. tINIT, for instance,
receives a set of metabolic tasks as input to obtain the required reactions
to perform those tasks. The metabolic tasks, that should occur in all
cell types, were retrieved from [20]. A set of metabolites can be defined
in mCADRE and tINIT algorithms, ensuring the production of those by
the resulting models. These configurations and algorithm parameters
were set with default values from the original publications [20, 21].
4. Finally, the algorithm was run to reconstruct a hepatocytes metabolic
model. The final MBA models were constructed based on 50 interme-
diate metabolic models. According to [16], a larger number would be
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desirable, but the time needed to generate each model prevented larger
numbers of replications.
The workflow described above can be depicted in Figure 5.2.
Figure 5.2: The hepatocytes models reconstruction workflow encompasses
four main steps: 1- transformation of input data identifiers to model notation;
2 - conversion of gene scores to reaction score through the GPR associations,
by substitution of the operators And/Or by the functions Min/Max; 3- con-
figuration of the algorithms properties and data filtering based on thresholds;
4 - run the algorithm.
This pipeline was applied considering Recon 1 human metabolic model as
template. At the end, 12 hepatocytes metabolic models were reconstructed
based on the combination of four methods (MBA, mCADRE, tINIT, FAST-
CORE) and three data sources (CH and CM reaction sets, HPA and GEB).
5.2.5 Model validation
The quality of the metabolic models was further validated using the metabolic
functions that are known to occur in hepatocytes taken from HepatoNet1 [17].
This set includes a total of 433 functional tasks divided in two categories: 310
network tasks and 123 physiological tasks.
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Each task is composed by two sets of metabolites, that can be uptaken
and excreted by the model and an objective function which represents the
target metabolite to be produced. All reactions connected to the extracellular
environment, also called drains, not present in the task should be closed, i. e.
constrained not to allow any flux.
Internal metabolites are accepted in the metabolic task definition. In
this case, artificial reactions are added to the model to allow the uptake
or excretion of those metabolites. In the task validation process, it is as-
sumed that all internal metabolites involved, when present in the model,
can be consumed/produced. This assumption can be done without affecting
the final validation result because the model is consistent, i.e, all reactions
are able to carry flux, which implies that all present metabolites can be
produced/consumed.
A FVA for each reaction is performed to find reactions where the maximum
and minimum possible flux is equal to 0. Afterwards, these reactions will
be removed from the original model. This simplification of the model is
done before the validation process starts. Moreover, tasks with metabolites
not present in the model are tested without the uptake/excretion of these
metabolites. However, tasks will not be validated if the objective metabolite
is not present in the model.
Figure 5.3 shows the main model modifications by the integration of a
metabolic task.
5.2.6 Consensus model reconstruction
The final hepatocytes consensus model was reconstructed based on the 12
metabolic models obtained by the process described above. The main idea is
to build a model starting with the common reactions present in most of the
models and append a set of reactions to the final model so, it will be able to
perform all the metabolic tasks. The final reconstruction consisted on three
main steps:
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Figure 5.3: A) Consistent metabolic model, where all the reactions are able
to carry flux. B) Metabolic task to simulate the production of metabolite m8,
allowing the uptake of M1e andM2e and assuming that m6 is produced in
the model. C) Modifications to the system: close all drains not present in the
metabolic task and insert artificial drains for the internal metabolite. The red
lines represent the flux distribution after maximizing the objective function.
1. Build 12 partial−models, hereafter designed as pModels, where the ith
model contains the reactions present in at least i hepatocytes models,
where i ∈ {1, 2, ...12}. Therefore, pModel1 contains the union of all
reactions from the 12 models, while pModel12 contains only the reactions
present in the intersection of all models. Additionally, the template
model Recon 1 is considered as pModel0.
2. Run the validation tasks process for each pModel and choose a value of
n, where pModeln is the smallest model with an acceptable number of
valid tasks. .
3. Next, it is necessary to calculate the reactions and valid task sets that
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differ between 2 neighbouring models (i.e. models with indexes i and
i+ 1). As a result, two lists are created, the lost reactions set (LRS)
and the lost metabolic tasks set (LMT). Each lost metabolic tasks set,
LMTi represents the set of tasks satisfied by pModeli, when compared
with pModeli+1. Similarly, each LRS set, LRSi, represents the reactions
present in pModeli and not in pModeli+1.
4. Finally, run Algorithm 4 to generate the final model. The algorithm
starts with pModeli, and taking into consideration the LRSi and LMTi,
finds the reactions of LRSi that are not required to perform the tasks
in LMTi. These reactions compose the toDeli set. At the end of each
iteration, the reactions that do not have an influence in the loss of
metabolic tasks performance, between two partial models (toDeli), are
appended to the LRSi−1 in the next iteration. The process ends with
the processing of pModel0, in this case the full Recon 1 model.
Figure 5.4 shows the steps in the reconstruction of the consensus final
model algorithm.
5.3 Results
The hepatocytes metabolic models were generated using Recon 1 the as
template model and the GEB, HPA and the CH and CM sets from [16] as
input data, by the four methods considered in this study: MBA, tINIT,
mCADRE and FASTCORE.
Three main questions were answered: Are omics data consistent across
different data sources? What is the overlap of the resulting metabolic models
obtained using different methods and different data sources? How do the
obtained models behave in functional terms regarding metabolic tasks?
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Algorithm 4 Reconstruct the final model based on pseudo-models.
function buildFinalModel(pModels, n, LMT , LRS)
toDel = {}
for i ∈ {n, n− 1, .., 0} do
finalModel = pModeli
reacsi = LRS[i]
tasksi = LMT [i]
for (r ∈ reacsi ∪ toDel) do
allV alidWithKO = isAllV alid(finalModel, tasksi, r)
if (allV alidWithKO) then
finalModel = finalModel\r
toDel = toDel ∪ r
end if
end for
end for
return finalModel
end function
function isAllValid((finalModel, tasksi, r))
Test if all tasks present in tasksi are satisfied by the finalModel when
the reaction r is removed.
end function
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Figure 5.4: A) Build the lost reaction set (LRS) and the lost metabolic
tasks set (LMT) between each par of partial models. B) For each pModeil
the process find the reaction from LRSi that can be removed from pModelI
without affect the metabolic tasks present in (LMTi) production. The set of
reactions that can be removed will be added to LRS set in the next iteration.
5.3.1 Omics data consistency
The HPA (version 12) has evidence information related with 16324 genes
in hepatocytes. The reliability of the data is also scored as “supportive”
or “uncertain”, depending on similarity in immunostaining patterns and
consistency with protein/gene characterization data [84]. On the other hand,
the GEB transcriptome (HGU133plus2 cells v3) has information for 20149
genes, of which 5772 have evidence of being expressed in hepatocytes [96].
Together, these two data sources have information for 21921 genes, but
only 14552 are present in both (Figure 5.5A). Moreover, the number of genes
with evidence of being expressed in the tissue in both sources is only of
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3549, around 24% of all shared genes (Figure 5.5B). These numbers decrease
significantly if using only HPA information marked as “supportive”. In this
scenario, only 3868 genes are present also in GEB and only 1294 of them have
expression evidence.
Figure 5.5: A) Number of genes present in Gene Expression Barcode and Hu-
man Protein Atlas. In HPA, the number of genes with reliability “supportive”
and “uncertain” are shown. B) Number of genes with evidence level “Low”,
“Moderate” or “High” in HPA and gene expression evidence higher than 0 in
Gene Expression Barcode.
Next, evidence levels frequencies (High, Moderate, Low) were calculated
across the GEB and HPA, as shown in Figure 5.6 using the thresholds of
Table 5.3.
Only a small number of genes have similar evidence levels in both data
sources. Furthermore, a significant number of genes have contradictory levels
of evidence - genes with expression evidence in one data source and not
expressed in the other.
Regarding the HPA data, only the information scored as ”supportive” was
considered in this work. Despite the number of genes present in HPA and
GEB repositories was higher, only the genes present in the template metabolic
model are useful in the hepatocytes models reconstruction. The Figure 5.7
shows the overlap between the data sources and the genes present in Recon 1.
From the genes present in the Recon 1 model with information in GEB
and HPA (supportive), there are 15% of genes with “High’” or “Moderate”
5.3 Results 101
Figure 5.6: A) Distribution of genes from Gene Expression Barcode project
and Human Protein Atlas across the evidence levels - “High”, “Moderate”
and “Low”. The ranges [0.9, 1], [0.5, 0.9[ and [0.1, 0.5[ were used to classify the
data into “Low”, “Moderate” and “High” levels. B) Genes with no evidence
to be present in hepatocytes from GEB, but with evidence in the HPA. C)
Genes with no evidence to be present in hepatocytes from HPA, but with
evidence in GEB.
Figure 5.7: Number of metabolic genes present in the human metabolic
models Recon 1 with evidence in HPA(suportive), GEB, both and none of
the omic data types.
evidence in one of the sources and not expressed in the other. This number
increases to 22% if we also consider “Low” evidence level.
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As mentioned before, in the developed framework, all methods receive
reaction scores calculated based on omics data. Thus, it was necessary to
convert the gene expression evidence levels from GEB and HPA to reaction
scores through the GPR associations. After this, the transformation impact
of omics discrepancies in the values of reaction scores was analysed and those
were compared to the manually curated set CH from Jerby et al. [16].
In Figure 5.8 A, the poor overlap of the reaction scores calculated based
on different sources can be observed. Considering all data sources and Recon
1 as generic model, 1903 reactions show some evidences that support their
inclusion in the hepatocytes metabolic model, but only 386 are supported by
all sources. The numbers are further dramatically reduced if we consider only
moderate or high levels of evidence (Figure 5.8 B-C).
Figure 5.8: Overlap of reaction evidence levels for the three input data sources
(CH and CM , GEB and HPA) A) Reactions with evidence that support their
inclusion in the hepatocytes metabolic model. B) Number of reactions that
have a high level of evidence of expression for each data source. C) Number
of reactions that have a moderate evidence of expression for each data source.
5.3.2 Hepatocytes metabolic models
The resulting metabolic models have between 1178 and 2139 reactions. Table
5.4 presents the size of each model reconstructed in this study.
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Table 5.4: Number of reactions for all hepatocytes metabolic models.
CH and CM HPA GEB
MBA 1748 1246 1577
tINIT 1750 11837 2139
mCADRE 1760 1178 1511
FASTCORE 1817 1220 1542
The Figure 5.9 shows the relations between the 12 metabolic models
generated through hierarchical clustering considering the Euclidean distance
as measure. This was done using the hclust function on the R software.
The models obtained using the CH and CM sets as input data group
together. Regarding the remaining, the mCADRE and MBA resulting models
group according to their data (HPA and GEB), while the models created by
tINIT cluster together (Figure 5.9). Overall, the data used as input seems to
be the most relevant factor in the final result.
Figure 5.9: Results from hierarchical clustering of the resulting 12 models for
each human generic metabolic model.
A more detailed comparison between the models reconstructed using the
same algorithm or the same data source is available in Figure 5.10, A and B
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respectively. Considering the models generated by the same algorithm, it is
observed that MBA has a smaller overlap (only 930 reactions) compared to
the other methods. This could be explained by the fewer number of metabolic
models generated for the reconstruction of the final consensus model.
Figure 5.10: Hepatocytes metabolic models reaction intersection considering:
(A) the same algorithm; (B) the same omics data source.
A lower number of reactions does not mean that the algorithm or data
source have poor overlap. So, the correlation of model size and the number
of reactions present in all models is presented in Table 5.5 to simplify the
analysis of the models overlap.
The values presented above show that the same input data under different
algorithms produces metabolic models with lower variance than using the
same algorithm for different omics data type. Furthermore, the mean of
reactions that belong to all models of the same algorithm is around 66%,
and around 78% when the models are grouped by data source. Again, the
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Table 5.5: Percentage of number of reactions of each model that are present
in the intersection of models with the same omics data as input or algorithm.
Algorithm Input Data ∩ Omics ∩ Methods
MBA Sets 90% 53%
HPA 73% 59%
GEB 82% 75%
tINIT Sets 90% 74%
HPA 50% 71%
GEB 60% 61%
mCADRE Sets 89% 55%
HPA 77% 81%
GEB 85% 64%
FASTCORE Sets 86% 55%
HPA 75% 82%
GEB 84% 65%
variability of the final results seems to be dominated by the data source factor.
5.3.3 Models validation
A set of metabolic tasks known to occur in hepatocytes cells was previously
presented by Gille et al. [17]. Some of these tasks are impossible to satisfy
with Recon 1 as template metabolic model, because they use metabolites
which are not present in the model. Thus, these tasks and disease related
tasks will not be considered in the validation process.
The generic Recon 1 human metabolic model is able to satisfy 281 of the
remaining 363 metabolic functions tested. This set of 281 metabolic tasks was
validated in each hepatocyte metabolic model to analyse the quality of the
generated models. The Table 5.6 presents the model size and the percentage
of tasks that remains successful in the tissue-specific model when compared
with the generic metabolic model.
Here, it is clear that FASTCORE is able to produce consistent models
independent of the input data. tINIT also has a significant percentage of
valid tasks when the data source is HPA. However, generically the number of
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Table 5.6: Percentage of liver metabolic functions that each metabolic model
performs when compared with the template model - Recon 1.
CH and CM HPA GEB
MBA 14% 8% 22%
tINIT 5% 70% 29%
mCADRE 3% 24% 24%
FASTCORE 54% 47% 67%
satisfied metabolic tasks is very low compared with the performance of the
template metabolic model - Recon 1.
5.3.4 Final consensus model
The reconstruction process based on the combination of all models was done
to achieve the final consensus hepatocytes metabolic model. The number
reactions and the number of valid tasks satisfied by each of the partial models
can be observed in Figure 5.11.
The pModel1 contains all the reactions present in at least one of the 12
metabolic models. Furthermore, this partial-model is capable to satisfy all
the metabolic tasks as the Recon 1. As can be seen in the Figure 5.11 the
number of valid tasks decreasing between pModel6 and pModel7 is significant.
So, pModel6 was considered the starting point of the strategy of building the
final model based on the models combination.
At the end, a metabolic model with 1.859 reactions was obtained. This
model satisfies all the 281 metabolic tasks also satisfied by the template model
Recon 1 but keeping only 50% of the reactions.
Finally, Figure 5.12 presents the relation between the models size and
the number of satisfied tasks for all reconstructed models, including our
hepatocytes final consensus model.
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Figure 5.11: Each pModeli obtained by the 12 hepatocytes models combina-
tions, where the index i represents the minimum number of models required
for reactions to be present. Blue bars represent the number of reactions, and
orange bars the number of tasks satisfied by the partial-models.
Figure 5.12: Correlation between tasks and models size.
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5.4 Conclusion
In this chapter, a critical evaluation of the most important methods for the
reconstruction of tissue-specific metabolic models was presented. Moreover,
the consistency of information across important omics data sources was
analysed and these data were used to verify the impact of such differences in
the final metabolic models generated by each method.
The results show that metabolic models obtained depend more on the
data sources used as inputs, than on the algorithm used for the reconstruc-
tion. To validate the accuracy of the obtained metabolic models, a set of
metabolic functions that should be performed in hepatocytes was tested for
each metabolic model. Generically, the number of satisfied liver metabolic
functions was surprisingly low with exception of the models generated by
FASTCORE and tINIT when HPA data was used as input .
This shows that methods for the reconstruction of tissue-specific metabolic
models, based on a single omics data source, are not enough to generate high
quality metabolic models. Here, it was also presented a strategy to build a
final metabolic model using the combination of generated models through
different algorithms and data sources. This process shows that with a similar
number of reactions, it is possible to achieve a final model capable of satisfying
all possible metabolic tasks. However, this strategy depends on metabolic
functions knowledge which remains unknown for the most tissues / cell-types.
Methods to combine several omics data sources to rank the reactions
for the reconstruction process could be a solution to improve the results of
these methods. Indeed, this study emphasizes the need for the development
of reliable methods for omics data integration, which seem to be required
to support the reconstruction of complex models of human cells, but also
reinforce the need to be able to incorporate known phenotypical data available
from literature or human experts.
Chapter 6
Glioblastoma Model
Reconstruction and Analysis
In this chapter, the reconstruction process of the U-251 cell
line (a human cell line derived from a malignant glioblas-
toma tumor) metabolic model is described. The framework,
described in previous chapters, together with the Recon 1
human metabolic model used as template model, and data
retrieved from Human Protein Atlas and Gene Expression
Barcode, were used to achieve the final model. Moreover,
analyses were performed to validate the final model and com-
pare the resulting model with other models already available
for this cell line.
6.1 Cancer and glioblastoma
6.1.1 Hallmarks of cancer
Cancer is a collection of diseases characterized by unregulated cell growth
and the invasion of other tissues/organs in the body [123]. Cancer cells
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present a huge number of genetic changes that contribute to the abnormal cell
behaviour, specially in how they grow and divide when compared to normal
cells. The mutations occurring in the genome can originate two major types
of mutated genes that contribute to the development of cancer: oncogenes,
allowing cells to grow and survive when they should not, and tumor suppressor
genes with recessive loss of function [124]. In 2000, Hanahan and Weinberg
[125] defined six hallmarks of cancer which comprise biological capabilities
acquired during the development of cancer, described below:
• Sustaining proliferative signaling: normal cells control the growth
and division cycle through growth-promoting signals, which contribute
for the normal tissue architecture and function. In cancer cells, these
signals are deregulated leading to unregulated growth.
• Evading growth suppressors: normally, cells respond to inhibitory
signals to maintain homeostasis. In cancer, the acquired mutations
interfere with the response to growth inhibitory signals.
• Resisting cell death: normal cells are eliminated by apoptosis (pro-
grammed cell death) when they suffer different types of DNA damage.
Cancer cells have a variety of strategies to limit or circumvent apoptosis,
being the loss of TP53 tumor suppressor function one of the most well
known.
• Enabling replicative immortality: the number of cell divisions is
finite and controlled by the shortening of chromosomal ends, telomeres,
that occurs during DNA replication. Cancer cells maintain the length
of telomeres, which allows the unlimited replication of the cells.
• Inducing angiogenesis: cells depend on blood vessels to supply oxy-
gen and nutrients. In normal cells, the vascular architecture remains
mainly constant in adults. However, the formation of new vessels is
essential for tumor growth and survival.
• Activating invasion and metastasis: mutations in genes involved
in the cell-cell and cell-extracelular adhesion allow the movement of
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cancer cells to other parts of the body. This is a major cause of cancer
death, since the disease is not in a specific organ, but spread over the
whole body.
Recently, the authors added two emerging hallmarks of cancer to the
previous list [126]. The first is the reprogramming of energy metabolism
by cancer cells, while the second is the capacity of cancer cells to avoid the
attack and elimination by immune cells. Additionally, two new enabling
characteristics were also added by the authors: the genome instability and
mutations, and the tumour-promoting inflammation. Both characteristics
contribute for the acquisition of hallmark capabilities by cells.
Under aerobic conditions, normal human cells process glucose on mitochon-
drial oxidative phosphorylation to generate the energy required by cellular
processes. When oxygen is limited, cells can redirect the pyruvate generated
by glycolysis to produce lactate, instead of the oxidative phosphorylation.
Cancer cells tend to convert glucose to lactate even when oxygen is present.
This anomalous characteristic of cancer cell energy metabolism was observed
by Otto Warburg [127], and the phenomenon is known as the Warburg Effect
[128] (Figure 6.1).
6.1.2 Glioblastoma
Glioblastoma (GBM), also known as astrocytoma grade IV, is the most
common and aggressive type of brain cancer in adults [129]. Based on
their clinical and biological characteristics, GBMs can be divided into two
categories [130]. Primary GBMs are the most common, being characterized
by the amplification and mutations in the EGFR gene and the deletion of
the PTEN and CDKN2A genes [131]. The protein encoded by the EGFR
gene is a receptor for members of the epidermal growth factor family, which
leads to cell proliferation. The PTEN and the CDKN2A genes are known to
be important tumor suppressor genes [132, 133]. Secondary GBMs, contrary
to the previous category, affect younger patients who had been affected
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Figure 6.1: Schematic representation of oxidative phosphorylation, anaerobic
glycolysis, and aerobic glycolysis, also known as the Warburg effect. In the
presence of oxygen, normal cells metabolize glucose via oxidative phosphoryla-
tion. When oxygen is limited, cells redirect the pyruvate to lactate production.
Cancers cells tend to convert most of glucose to lactate even in the presence
of oxygen (aerobic glycolysis). Figure adapted from [128].
by a lower grade astrocytoma before. These GBMs are characterized by
mutations in the TP53 gene and overexpression of PDGFR [131]. Several
studies have identified alterations in the IDH1/2 genes (encode the cytosolic
and mitochondrial isoforms of NADP+-dependent isocitrate dehydrogenases),
that are also observed in secondary GBMs [129, 134, 135, 136].
These molecular abnormalities are present in both categories, but with
different frequencies. As an example, the frequency of TP53 mutation in
secondary GBM is more than 65%, but only 28% in primary GBM [137].
6.2 Phenotype simulation
The methods implemented in the developed framework for phenotype simula-
tion (GIMME, iMAT and E-Flux), described in sections 2.5 and 3.5, were
used to perform phenotype prediction of glioblastoma cells, under different
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conditions, using the Recon 1 as metabolic model and the transcriptomic
data retrieved from [138]. These data set were also available in GEO with the
accession identifier GSM803632. The biomass equation used in the simulations
was taken from the Recon 2 metabolic model.
The biomass flux rate obtained using the FBA simulation method was
of 0.084 mmol/gDW/hr, using the RPMI-1640 medium as described in
[139]. The phenotype simulations given by GIMME and iMAT also took
into consideration this medium. The E-Flux algorithm formulation assumes
the value -1 as the lower bound for all uptake fluxes, so the medium is not
considered in the phenotype simulation.
In chapter 4, it was observed that the phenotype predictions using pFBA
have a lower prediction error associated, when compared with the other
simulation methods. Similarly to this previous study, we compare the flux
exchange rates obtained by different methods with the experimental values
taken from [140]. This data set contains the measurements, obtained using
mass spectrometry, of consumption and release profiles of 219 metabolites
from the medium across the NCI-60 cancer cell lines. From all measured
metabolites, only 36 were considered in this analysis, since these have an
exchange reaction associated in the Recon 1 metabolic model. All values from
the simulation results were normalized by the glucose uptake.
The normalized prediction errors for each method are presented in Table
6.1. Once again, the estimation error was calculated using the equation:
error =
‖vexp − vsim‖
‖vexp‖
(6.1)
where vexp is the vector of measured flux values and vsim is the vector of
predicted values.
In chapter 4, and also in Machado et al. [111], the pFBA method achieves
better results when compared with the other simulation methods. However,
this is not observed in this case. Here, the GIMME and iMAT methods
have a better prediction capability when compared with pFBA. So, it seems
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Table 6.1: The normalized prediction errors, associated to the simulation
methods pFBA, GIMME, E-Flux and iMAT, for glioblastoma phenotype
prediction using the Recon 1 as a metabolic model.
pFBA E-Flux GIMME iMAT
Error 0.9152 1.0004 0.7484 0.7598
that transcriptomic data can play an important role in the improvement of
phenotype predictions of metabolic models, at least in some cases.
6.3 Tissue-specific model reconstruction
Recon1 was used as the template model to the glioblastoma metabolic model
reconstruction. The main reasons for this choice are related to the size of the
model, being the time consummed to generate the tissue-specific models much
lower than using other metabolic models as Recon 2, and the possibility to eas-
ily compare the resulting model with already published glioblastoma metabolic
models [21, 23]. The input data used by the reconstruction algorithms present
in our framework were retrieved from HPA and GEB databases. We used
these two data sources in combination with four reconstruction methods to
achieve the final U-251 metabolic model.
6.3.1 Omics data sources
The reconstruction of the U-251 metabolic model starts with the collection of
information from omics databases. HPA and GEB have transcriptomics and
proteomics evidences for this cell line.
The Recon 1 metabolic model, used as template in the reconstruction of
tissue-specific models, has 1905 genes. The HPA and GEB databases have
information for 1335 and 1293 genes from the Recon1. The Figure 6.2-A shows
that most of the genes are present in both databases. However, if we take
into account the expression evidence levels, the number of genes and reactions
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with the same evidence level is surprisingly low (Figure 6.2-B,C). The gene
expression levels present in the omics data sources were converted to reaction
evidence levels through the gene-protein-reactions(GPR) rules present in the
metabolic model. During the conversion, the operators AND/OR present in
the GPRs are substituted by the MIN/MAX functions, respectively.
Figure 6.2: Genes with expression evidence for U-251 cell line in Human
Protein Atlas (HPA) and Gene Expression Barcode (GEB). The red numbers
represent the number of reactions with evidence to be active (using the
Gene-Protein-Reaction rules present in the model) and the black numbers
the number of genes. A) Intersection of genes present in both data sources
and in the Recon 1 metabolic model. B, C) Recon 1 genes and reactions with
high (B) and moderate(C) evidence to be expressed in the U-251 cell line.
The lower overlap in the high and moderate sets of reactions considering the
cutoffs of ”High”/ 0.9 and ”Medium”/ 0.5 from data retrieved from HPA/GEB
can have a significant impact in the resulting models, independently of the
used algorithm.
The reconstruction of the tissue-specific metabolic models was done con-
sidering the cutoffs already present in Table 5.3 on chapter 5.
6.3.2 U-251 metabolic models
Following the same approach used on chapter 5, eight U-251 cell line metabolic
models were created. Each model was reconstructed using one of the available
algorithms in your framework ( FASTCORE, MBA, mCADRE and tINIT)
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and an omics data source (HPA and GEB). The size of each model is presented
on Table 6.2.
Table 6.2: Number of reaction of each U-251 metabolic model.
Algorithm Data Source Reactions
MBA HPA 1563
GEB 1752
mCADRE HPA 1170
GEB 1110
tINIT HPA 2048
GEB 1146
FASTCORE HPA 1219
GEB 1137
Figure 6.3 shows the overlap of the resulting models from the different
methods, when each of the omics data source was considered.
Figure 6.3: Reactions overlap of U-251 metabolic models grouped by data
source (HPA and GEB).
Comparing the U-251 models, reconstructed with the same data source,
tINIT and MBA algorithms produce models with a higher number of exclusive
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reactions, i.e., reactions present in a single model. The number of reactions
shared by all models for each data source is similar, 913 and 804 for HPA and
GEB data sources, respectively. However, the intersection of these two sets is
only of 577 reactions.
Figure 6.4 presents the intersection of these same models, but considering
the algorithm instead of the data source as categories.
Figure 6.4: Reactions overlap of U-251 metabolic models grouped by algo-
rithms (MBA, FASTCORE, mCADRE and tINIT).
Considering the models generated by the same algorithm, it is observed
that MBA has the highest overlap when compared to the other methods.
However, with exception of tINIT HPA metabolic model, the MBA models
have a significant increase in the number of reactions, when compared with
other models. The mCADRE and FASTCORE models have a similar number
of reactions and the models generated by HPA and GEB are also of similar
size. In order to explore the similarity of the models, the Figure 6.5 depicts
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the hierarchical clustering of the U-251 metabolic models.
Figure 6.5 presents the intersection of these same models, but considering
the algorithm, instead of the data source as a discriminant factor.
Figure 6.5: Hierarchical clustering of U-251 metabolic models.
The mCADRE and FASTCORE models are grouped first by data source,
and then by the algorithm used in the reconstruction process. The MBA
models depend more on the algorithm than on the data source used to build
the U-251 models. The models reconstructed by tINIT belong to different
branches of the tree, showing that the data source used as input can have a
huge influence on the result.
One of the hallmarks of cancer is the capability that cancer cells have
to proliferate. To address this issue, FBA simulations were done to test
the biomass production of each model. The biomass equation was collected
from the Recon 2 metabolic model and the RPMI-1640 medium [139] has
been considered in all simulations. As a result, none of the models was able
to produce biomass. So, we tested how many biomass precursors could be
produced in each metabolic model, by adding additional reactions to excrete
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each biomass precursor and simulating the maximization of these reactions.
Table 6.3 presents the number of biomass precursors produced by each of the
U-251 metabolic models.
Table 6.3: Number of biomass precursors produced by each of the U-251
metabolic models. The biomass equation was obtained from Recon 2 metabolic
model which contains 38 precursors metabolites.
Algorithm Data Source Nr. of Precursors % of Precursors
MBA HPA 26 68%
GEB 25 68%
mCADRE HPA 5 13%
GEB 12 32%
tINIT HPA 31 82%
GEB 17 45%
FASTCORE HPA 19 50%
GEB 16 42%
The U-251 model generated by the tINIT algorithm using HPA data has
the highest number of biomass precursors satisfied. This is expectable since
this model has approximately 500 more reactions than the remaining models.
Given these results, the reconstruction of a single, unified and global U-251
metabolic model is required. The final metabolic model must be able to carry
flux on the biomass reaction, to allow to simulate the proliferation of cells,
predicting growth rate.
6.3.3 Consensus model
The final U-251 metabolic model was built considering all previously recon-
structed models by different methods and data sources. The process, already
detailed in section 5.2.6, starts with the reconstruction of the partial models
(pModeli i ∈ 1, ..8). Each partial model (pModeli) contains the reactions
present in at least i U-251 metabolic models. Thus, the pModel5 for instance
contains all reactions present in five or more models from the set of eight
models.
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Here, the tasks are defined by the production of biomass precursors. So,
we checked how many biomass precursors each partial model was able to
produce. Figure 6.6 depicts the number of reactions and the number of
biomass precursors produced by each pModel.
Figure 6.6: Number of reactions (green bars) and number of biomass precursors
that can be produced (orange bars) by the pModels. The pModel8 was ignored
since the previous pModel does not produce any of the biomass precursors.
As can be observed in the picture, the highest decrease on the number of
produced biomass precursors occurs between pModel4 and pModel5. Thus,
the process of reconstructing the final consensus model starts with pModel4
as the initial model. In each iteration, the algorithm takes as input a partial
model (pModeli) and tries to remove the maximum number of reactions
that were lost between pModeli and pModeli+1, maintaining the biomass
precursors produced by pModeli and not by pModeli+1. In this case, the lost
reaction set (LRS) and the lost biomass precursors set (LBS) are composed
by the difference between the two partial models pModel4 and pModel5. At
the end of each iteration, the reactions that do not have an influence in the
loss of biomass precursors between two partial model (toDeli), are appended
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to the LRS in the next iteration. The process ends with the processing of
pModel0, in this case the full Recon 1 model. Figure 6.7 shows the steps in
the reconstruction of the consensus final model.
Figure 6.7: A) Build the lost reaction set (LRS) and the lost biomass precursors
set (LBS) between each par of partial models. B) For each pModei the process
find the reaction from LRSi that can be removed from pModelI without affect
the biomass precursors (LBSi) production. The set of reactions that can be
removed will be added to LRS set in the next iteration.
The final consensus model obtained is composed of 922 genes, 1.376
metabolites and 1.457 reactions. This model is able to simulate the biomass
production, through FBA, using the RPMI-1640 medium [139]. The flux
rate for biomass equation is around 0.0291 mmol/gDW/hr. Although the
lower biomass flux rate, when compared with the original model Recon 1
(0.084 mmol/gDW/hr), this process is able to achieve a final consensus model
based in all previous models capable to simulate the biomass production.
122 Glioblastoma Model Reconstruction and Analysis
6.4 Critical genes
The validation of metabolic models is a hard task when fluxomics data are
not available. So, some tests were done to check if the consensus metabolic
model has a better phenotype prediction capability than the global model
Recon 1.
As a first validation, we calculated the predicted critical genes of both
models. We considered critical genes as the genes that inhibit growth when
they are removed from the model. We obtained these gene sets through FBA
simulations, when each gene present in the model was knocked out, i.e. the
reactions associated through GPRs to this gene were constrained to have
no flux. At the end, the final consensus model of the U-251 cell line has 89
critical genes, of which 80 are also critical genes in Recon 1. Thus, nine genes
are only critical on the U-251 metabolic model - G6PT2, SLC5A7, NME2,
NME1, SLC6A14, PTDSS1, SLC16A10, CDS1, CTPS. Remarkably, most
of these genes have been associated to cancer cell growth in several research
studies. The function and the relevance of these genes on glioblastoma cancer
cells are detailed next:
• The G6PT2 gene regulates the Glucose-6P transport from cytoplasm
to the lumen of the endoplasmic reticulum. Studies demonstrate that
intracellular signalling and invasive phenotype of brain tumor cells could
be regulated by this gene [141]. Moreover, silencing the G6PT gene in
U-87 brain tumor-derived glioma cells induce necrosis and late apoptosis
[142]. Thus, control of the G6PT expression can lead to the development
of new strategies to prevent cancer development in glial cells.
• The SLC5A7 gene encodes a high-affinity choline transporter. Choline
is used for the synthesis of essential lipid components of cell membranes
[143]. A higher choline concentration in the cells has been related with
cell proliferation and malignant progression of cancer [144, 145] being
the abnormal choline metabolism considered, by Glunde et al., as a new
hallmark of cancer [146]. Kumar et al. [147] demonstrate that using
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specific choline kinase inhibitors may be a promising new strategy for
treatment of brain tumors.
• The SLC6A14 gene encodes the protein called sodium- and chloride-
dependent neutral and basic amino acid transporter B(0+) which can
transport all essential amino acids, as well as glutamine, arginine, and
asparagine [148]. Cancer cells, to support their rapid cell growth,
induce the over-expression of this gene. This phenomenon has been
observed in cervical cancer, colorectal cancer and breast cancer cell lines
[149, 150, 151]. The SLC6A14 deletion was studied in mouse models of
breast cancer by Badu et al. [152]. The study demonstrated that the
development and progression of breast cancer were markedly decreased
in vitro and in vivo when SLC6A14 is deleted.
• The CDS1 is a protein coding gene which regulates the amount of
phosphatidylinositol available for signaling by catalyzing the conversion
of phosphatidic acid to CDP-diacylglycerol. CDP-diacylglycerol is an
important precursor for the synthesis of phosphatidylinositol (PtdIns),
phosphatidylglycerol, and cardiolipin [153, 154]. The cardiolipin com-
pound is one of the biomass precursors present in Recon 2 biomass
equation. Thus, its production is essential.
• ThePTDSS1 gene encodes phosphatidylserine synthase 1 (PSS1) which
is involved in the production of phosphatidylserine. This gene is involved
in a patent related to the development of a molecular-based method of
cancer diagnosis and prognosis. Together with five others genes, the
PTDSS1 has a higher expression in tumor samples when compared with
control samples [155].
• The CTPS gene encodes an enzyme responsible for the conversion
of UTP (uridine triphosphate) to CTP (cytidine triphospate). The
development of methods and pharmaceutical compositions to inhibit
the lymphocyte proliferation through the CPTS1 inhibitors has been
protected by a patent [156].
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• The NME2 / NME1 genes were identified as potential tumor suppres-
sors, which reduce the tumor progression and proliferation [157]. Thus,
it was unexpected that these genes were essential for the metabolic
model. To understand this result, we did a deep analysis of the reactions
where these genes are involved. The two genes regulate the activation of
nucleoside-diphosphate kinase reactions in the nucleus. These reactions
are responsible to produce essential metabolites present in biomass
equation, namely Deoxyguanosine triphosphate (dGTP), Deoxycytidine
triphosphate (dCTP), Deoxyadenosine triphosphate (dATP) and De-
oxythymidine triphosphate (dTTP). These metabolites are used in cells
for DNA synthesis.
6.5 The Warburg effect
The phenomenon known as “Warburg effect” consists in the capability that
cancer cells have to generate the energy needed for cellular processes through
aerobic glycolysis instead of the oxidative phosphorylation, as normal cells do
[158]. The aerobic glycolysis is an inefficient way to achieve ATP production (2
ATP molecules per one glucose molecule), when compared with the oxidative
phosphorylation (32 ATP molecules per one molecule of glucose), leading to
lactate secretion [159].
In 2011, Shlomi et al. [12] argued that the Warburg effect is a conse-
quence of the metabolic adaptation of cancer cells to increase biomass. They
developed a new simulation method based on FBA which accounts for the
enzyme solvent capability as a constraint. In the study, it was clear that
the three phases (optimal, intermediate and low yield metabolism) observed
experimentally during oncogenic progression can be observed in the in silico
simulations.
Using the same approach, we tested if our model was able to simulate
the lactate secretion even in the presence of oxygen. Therefore, we used
our U-251 consensus model with the RPMI1640 medium as before, with
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different amounts of glucose uptake between 0 and the uptake value needed to
reach the maximal growth rate (0.14 mmol/gDW/h). The molecular weights
and turnover numbers used for the Recon 1 metabolic model reactions were
obtained from the original publication [12].
Using the FBA with solvent capacity constraints, the biomass yield de-
creases at high growth rates, as shown in Figure 6.8.
Figure 6.8: Predicted maximal growth yield of U-251 cell line (per unit of
glucose uptake) for a range of predicted growth rates obtained by simulation
of an extension of FBA which considers enzyme solvent capacity of the cells
[12].
Considering the lactate secretion and the oxygen consumption fluxes for
the range of growth rates, it is visible that the lactate production occurs even
in the presence of oxygen (Figure 6.9).
In the figure, three different phases in the growth yield are clear:
(i) Optimal yield - characterized by the absence of lactate production.
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Figure 6.9: Predicted lactate secretion flux (red line) and oxygen uptake
flux (green line) for a range of growth rates. Growth rates were obtained by
varying the glucose uptake rate limit from 0.0 to 0.14 mmol/gDWh/h. The
maximal growth rate is obtained when the glucose uptake is around of 0.1347
mmol/gDWh/h. Flux values were normalized by the glucose uptake rate.
Even with a small decrease of oxygen uptake the growth yield remains
constant.
(ii) Small decreasing in yield - in this phase, the growth yield has a small
decrease when compared with the previous phase. Moreover, the lactate
production has a significant increase and oxygen also increases, reaching
higher values when compared with the oxygen consumption values from
the previous phase.
(iii) Low yield - characterized by a sharp decrease in oxygen consumption,
lactate production fluxes and also growth yield. The method with
solvent capacity constraints used in the simulation could be the reason
for the decreasing of these fluxes (since the objective is the biomass
production all reactions that are not essential to biomass production
will decrease to minimum levels).
6.6 Other tissue-specific metabolic models 127
As a conclusion, the present model (consensus U-251 model) with the
incorporation of solvent capacity constraints lead to refined predictions of
cancer metabolic phenotypes, such as the Warburg effect.
6.6 Other tissue-specific metabolic models
Glioblastoma GSMMs were already reconstructed in previous studies [23, 21].
In this section, the overlap and a functional analysis between our model
and the previous models, also generated considering Recon 1 as a template,
are presented. The glioblastoma tumor cells and U-251 cell line GSMMs
reconstructed by mCADRE and PRIME algorithms respectively, were used
to perform the comparison with our consensus model. The overlap between
all glioblastoma metabolic models is provided in Figure 6.10.
Figure 6.10: Overlap of metabolic models. The PRIME and mCADRE models
are available in the methods publication articles. The consensus model is our
model, reconstructed during this study.
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Analyzing the model obtained by PRIME, we verified that the Recon
1 template model used by the algorithm is not the original model, but an
extended version which has 46 extra reactions. These reactions are essentially
for excretion of cytosol metabolites which can lead to significant differences
in the phenotype simulation results. The models PRIME, mCADRE and
Consensus are composed by 1952, 1131 and 1457 reactions respectively.
Next, we performed the phenotype prediction using the simulation methods
present in our framework (pFBA, iMAT, GIMME and E-Flux). Transcrip-
tomics data published by Gholami et al. [138] were used as input in the
simulation methods (the same data used in section 6.2). Experimental flux
values publised by Jain et al. [140] (also used in section 6.2) were used to
compare with the flux exchange rates obtained by different methods and the
normalized prediction errors were calculated using the equation 6.1.
In this study, the glioblastoma tumor cells metabolic model obtained by
the mCADRE reconstruction method was not considered, because this model
is not able to grow when simulated using the Recon2 biomass equation, even
with the removal of the metabolites present in the biomass equation and not
in the model.
The normalized prediction errors are given in Table 6.4.
Table 6.4: The normalized prediction errors, associated with the simulation
methods pFBA, GIMME, E-Flux and iMAT, for U-251 model reconstructed
by PRIME and consensus U-251 model.
pFBA E-Flux GIMME iMAT
Consensus 1.2866 0.7427 0.7639 0.7102
PRIME 0.7849 2.9739 0.7481 0.7461
Most of the method and model combinations have a normalized error
around 0.7. The best combination, reaching a lower prediction error was
obtained with the consensus U-251 metabolic model developed during this
study using the iMAT simulation method.
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6.7 Conclusion
In this chapter, the reconstruction process of our gliobastoma metabolic model
was presented. Several methods and data sources were used to reconstruct
metabolic models for the U-251 cell line (derived from a malignant glioblas-
toma tumor). The final model here presented was constructed based on all
these models and taking the biomass production, retrieved from Recon 2
human metabolic model, as a requirement.
Taking this model as reference, we calculated the list of essential genes for
the cell growth, and validated their function in published data. Most of the
genes have been associated with tumor growth inhibition in the literature.
Our glioblastoma metabolic model has also the capability to predict
the Warburg effect when the model is simulated by an extension of FBA,
which accounts for the enzyme solvent capability as a constraint. Moreover,
this model presents better results than other published model [23] when it
is simulated with transcriptomic data, and the predicted flux distribution
has a lower error comparing with experimental measurements for external
metabolites.
Based on these results, our automatically generated glioblastoma metabolic
model could represent a good starting point to achieve a curated metabolic
model with good phenotype predictions.

Chapter 7
Conclusions and Future Work
In the final chapter of this thesis, the main conclusions of
this work are presented. Some topics for future work are
put forward.
7.1 General conclusions
The work developed along this thesis had as main goal the development of
a framework for the reconstruction and analysis of tissue-specific metabolic
models. Additionally, three of the most used phenotype prediction methods,
published in recent years were also implemented, as well as a set of methods
that allow loading and integrating omics data with the genome-scale metabolic
models.
The clear division between the two layers, omics data processing and
simulation/reconstruction methods, in the framework allows to use different
omics data sources with the implemented methods. Moreover, the developed
plug-ins in the open-source OptFlux platform make it an attractive resource
to an ever increasing ME community.
The initial evaluation of the phenotype simulation methods implemented
in the framework confirmed the results from [111]. In both case studies, the
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pFBA method has a lower prediction error than the iMAT, GIMME and
E-Flux methods, taking into account 36 experimental measured fluxes.
Next, the critical evaluation of the methods for the reconstruction of
tissue-specific models showed that the omics data sources used in the building
process have more impact in the final result than the method itself. This
emphasizes the need for the development of reliable methods to integrate and
compile information from different data sources.
Furthermore, the results reveal that, for a specific case of hepatocytes cells,
none of the methods was capable of originating a tissue-specific model which
satisfies all the metabolic tasks performed by the template model and related
with the liver function. So, a strategy to build a consensus final metabolic
model using the combination of generated models through different algorithms
and data sources was developed to improve the prediction capability of the
final model. However, this strategy depends on metabolic functions knowledge
which remains unknown for most tissues / cell-types.
Finally, we reconstruct a metabolic model for U-251 cell line , targeting
the understanding of metabolic alterations related glioblastoma, one of the
most aggressive tumors in humans. The final model was reconstructed based
on metabolic models obtained using different methods and data sources. This
model achieves better results when compared with other models for the same
phenotype. The automatic reconstruction of a consensus model shows that
is a good starting point to achieve a curated metabolic model with good
phenotype predictions.
In summary, the developed framework helps in the reconstruction of
tissue-specific metabolic models and allows the usage of phenotype prediction
methods by common users through plug-ins in OptFlux. Additionally, the
development of new methods by programmers can be easily done by extending
the current framework.
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7.2 Topics for future work
The framework and related plug-ins developed during this thesis provided a
valuable contribution for the systems biology community. Nevertheless, some
topics can be explored in future work:
• Development of new methods for the reconstruction of tissue-specific
models based on meta-heuristics from the field of Evolutionary Compu-
tation, since these allow the competition of hypothetical models and
the definition of flexible objective functions.
• From a software development perspective, an ongoing objective is the
development of a new plug-in to support the methods for the tissue-
specific reconstruction methods. At the moment only programmers, or
at least users with a good working knowledge of command-line tools, are
able to use the framework to reconstruction of tissue-specific metabolic
models.
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